Patent Grant
11564642
The present disclosure relates generally to the field of detecting an opioid overdose, and in particular, to detecting low saturation of oxygen in the blood of an opioid user, and automatically notifying a responder.
Substance abuse disorders impact the lives of millions of people. An opioid overdose can occur when a person overdoses on an illicit opioid drug, such as heroin or morphine. Many controlled substances are prescribed by physicians for medical use. Patients can accidentally take an extra dose or deliberately misuse a prescription opioid. Mixing a prescription opioid with other prescription drugs, alcohol, or over-the-counter-medications can cause an overdose. Children are particularly susceptible to accidental overdoses if they take medication that is not intended for them. Opioid overdose is life-threatening and requires immediate emergency attention.
An opioid overdose is toxicity due to an excess or opioids. Symptoms of an opioid overdose include marked confusion, delirium, or acting drunk; frequent vomiting; pinpoint pupils; extreme sleepiness, or the inability to wake up; intermittent loss of consciousness; breathing problems, including slowed or irregular breathing; respiratory arrest (absence of breathing); respiratory depression (a breathing disorder characterized by slow and ineffective breathing); and cold, clammy skin, or bluish skin around the lips or under the fingernails.
Depressed breathing is the most dangerous side effect of opioid overdose. Lack of oxygen to the brain can not only result in permanent neurologic damage, but may also be accompanied by the widespread failure of other organ systems, including the heart and kidneys. If a person experiencing an opioid overdose is left alone and asleep, the person could easily die as their respiratory depression worsens.
Oximetry can be used to detect depressed breathing. Oximetry utilizes a noninvasive optical sensor to measure physiological parameters of a person. In general, the sensor has light emitting diodes (LEDs) that transmit optical radiation into a tissue site and a detector that responds to the intensity of the optical radiation after absorption (e.g., by transmission or transreflectance) by, for example, pulsatile arterial blood flowing within the tissue site. Based on this response, a processor can determine measurements for peripheral oxygen saturation (SpO2), which is an estimate of the percentage of oxygen bound to hemoglobin in the blood, pulse rate, plethysmograph waveforms, which indicate changes in the volume of arterial blood with each pulse beat, and perfusion quality index (e.g., an index that quantifies pulse strength at the sensor site), among many others.
It is noted that “oximetry” as used herein encompasses its broad ordinary meaning known to one of skill in the art, which includes at least those noninvasive procedures for measuring parameters of circulating blood through spectroscopy. Moreover, “plethysmograph” as used herein (commonly referred to as “photoplethysmograph”), encompasses its broad ordinary meaning known to one of skill in the art, which includes at least data representative of a change in the absorption of particular wavelengths of light as a function of the changes in body tissue resulting from pulsing blood.
An oximeter that is compatible with a hand held monitor, such as a mobile computing device, can be used to monitor physiological parameters. The oximeter can detect decreased oxygen saturation in the blood of the user. Decreased oxygen saturation in the blood of the user is an indication of respiratory distress, which can be an indication of opioid overdose. Once the oxygen saturation of the user falls below an acceptable threshold, a software application in the mobile computing device can alert others to provide emergency help. The threshold can be set to provide an early indication of an overdose event. If the overdose is caught early, emergency treatment can be provided before irreparable harm occurs.
A system to monitor for indications of opioid overdose and to deliver therapeutic drugs can comprise a sensor wearable by a user configured to obtain data indicative of at least one physiological parameter of the user; a signal processor configured to process the data to provide the at least one physiological parameter; and a drug delivery apparatus wearable by the user and configured to deliver one or more doses of a therapeutic drug. The drug delivery apparatus can comprise a delivery device that includes a dose of a therapeutic drug stored in a reservoir, a drug delivery channel, a dispensing device to dispense the therapeutic drug from the reservoir through the drug delivery channel, and activation circuitry to activate the dispensing device.
The system can further comprise a medical monitoring hub configured to monitor the at least one physiological parameter. The medical monitoring hub can comprise memory storing instructions and one or more computer processors configured to execute the instructions to at least compare the at least one physiological parameter to a threshold that is indicative of opioid overdose; determine that an overdose event is occurring or likely to occur based on the comparison; and send at least one activation signal to the drug delivery apparatus to dispense at least one dose of the therapeutic drug based on the determination.
The one or more computer processors of the medical monitoring hub can be further configured to provide an alarm in response to determining that the overdose event is occurring or likely to occur; wait a period of time after providing the alarm before sending the at least one activation signal; where receiving user input during the period of time stops the sending of the at least one activation signal. The one or more computer processors of the medical monitoring hub can be further configured to receive an indication of medical distress of the user; and send a notification of the medical distress to one or more contacts, wherein the one or more contacts include medical professionals, relatives, friends, and neighbors.
The system can further comprise a housing that houses the sensor, the signal processor, and the drug delivery device. The drug delivery apparatus can further include a first antenna and a first processor in communication with the first antenna, where the sensor can further include a second antenna and a second processor in communication with the second antenna, and where the first and second processors can be configured to provide wireless communication between the drug delivery device and the sensor. The drug delivery apparatus can be a single use drug delivery apparatus. The drug delivery device can further include an antenna to receive an activation signal. The drug delivery apparatus can include at least two drug delivery devices.
The medical monitoring hub can be in communication with a remote server comprising a user database, memory storing instructions, and one or more computing devices configured to execute the instructions to cause the remote server to access user information associated with the user in the user database. The user information can include contact information of contacts to notify with overdose status of the user.
The one or more computing devices of the remote server can be further configured to send notification of the overdose event to at least one contact. The notification can include one or more of a location of the user, a location of an opioid receptor antagonist drug, and an indication of the at least one physiological parameter. The notification can be one or more of a text message, an email, a message on social media, and a phone call.
The system can further comprise a smart device in communication with the signal processor to receive the at least one physiological parameter and in communication with the medical monitoring hub. The smart device can comprise memory storing instructions, and one or more microprocessors configured to execute the instructions to at least compare the at least one physiological parameter to the threshold that is indicative of opioid overdose; determine that the overdose event is occurring or likely to occur based on the comparison; determine that the medical monitoring hub failed to send the at least one activation signal; and send the at least one activation signal to the drug delivery apparatus to dispense at least one dose of the therapeutic drug in response to the determination that that the medical monitoring hub failed to send the at least one activation signal. The memory of the smart device can further store the contact information and the one or more microprocessors of the smart device can be further configured to notify the contacts of the overdose event.
The drug delivery apparatus can comprises a patch and can include an adhesive layer for adhesion to the user. The at least one physiological parameter can comprise one or more of oxygen saturation, heart rate, respiration rate, pleth variability, and perfusion index. The medical monitoring hub can further comprise an input to receive user input, a speaker, and alarm circuitry, and where the one or more computer processors of the medical monitoring hub can be further configured to produce an alarm based on the determination. Volume of the alarm can increase until user input is received. A kit can comprising any of the systems disclosed herein.
A medical monitoring hub to monitor for indications of opioid overdose can comprise memory storing instructions and one or more computer processors configured to execute the instructions to at least receive data indicative of at least one physiological parameter of a user that is obtained by a user-wearable sensor; process the data to provide the at least one physiological parameter; compare the at least one physiological parameter to a threshold that is indicative of opioid overdose; determine that an overdose event is occurring or likely to occur based on the comparison; and send at least one activation signal to a drug delivery apparatus to dispense at least one dose of the therapeutic drug based on the determination. The drug delivery apparatus wearable by the user can be configured to deliver one or more doses of a therapeutic drug.
The drug delivery apparatus can comprises a delivery device that includes a dose of a therapeutic drug stored in a reservoir, a drug delivery channel, a dispensing device to dispense the therapeutic drug from the reservoir through the drug delivery channel, and activation circuitry to activate the dispensing device. The drug delivery apparatus can comprise one or more delivery devices. Each drug delivery device can comprise a dose of a therapeutic drug stored in a reservoir, a drug delivery channel, a dispensing device to dispense the therapeutic drug from the reservoir through the drug delivery channel, activation circuitry to activate the dispensing device, and an antenna to receive the at least one activation signal. Each antenna can be tuned to receive a corresponding activation signal at a different frequency. The one or more computer processors can be further configured to send two or more activation signals. Each of the two or more activation signals can have the different frequencies to cause corresponding two or more activation circuitry to activate to dispense two or more doses of the therapeutic drug at approximately the same time.
A method to monitor for indications of opioid overdose and to deliver therapeutic drugs can comprise obtaining, from a sensor wearable by a user, data indicative of at least one physiological parameter of the user; processing, with a signal processor, the data to provide the at least one physiological parameter; and delivering, from a drug delivery apparatus wearable by the user, one or more doses of a therapeutic drug. The delivering can comprise activating a dispensing device that is configured to dispense through a drug delivery channel a dose of therapeutic drug stored in a reservoir; and dispensing with the activated dispensing device, the dose of the therapeutic drug from the reservoir through the drug delivery channel.
The method can further comprise monitoring, with a medical monitoring hub that can comprise one or more computing devices, the at least one physiological parameter. The monitoring can comprise comparing the at least one physiological parameter to a threshold that is indicative of opioid overdose; determining that an overdose event is occurring or likely to occur based on the comparison; and sending at least one activation signal to the drug delivery apparatus to activate the dispensing device based on the determination. The method can further comprise providing an alarm in response to determining that the overdose event is occurring or likely to occur; and waiting a period of time after providing the alarm before sending the at least one activation signal, where receiving user input during the period of time can stop the sending of the at least one activation signal. The method can further comprise receiving an indication of medical distress of the user; and sending a notification of the medical distress to one or more contacts, wherein the one or more contacts include medical professionals, relatives, friends, and neighbors.
The sensor, the signal processor, and the drug delivery device can be housed in a single housing. The drug delivery apparatus can further include a first antenna and a first processor in communication with the first antenna, where the sensor can further include a second antenna and a second processor in communication with the second antenna. The first and second processors can be configured to provide wireless communication between the drug delivery device and the sensor. The drug delivery apparatus can be a single use drug delivery apparatus. The drug delivery device can further include an antenna to receive an activation signal. The drug delivery apparatus can include at least two drug delivery devices.
The medical monitoring hub can be in communication with a remote server that can comprise a user database, memory storing instructions, and one or more computing devices configured to execute the instructions to cause the remote server to access user information associated with the user in the user database. The user information can include contact information of contacts to notify with overdose status of the user.
The method can further comprise sending, with the remote server, notification of the overdose event to at least one contact. The notification can include one or more of a location of the user, a location of an opioid receptor antagonist drug, and an indication of the at least one physiological parameter. The notification can be one or more of a text message, an email, a message on social media, and a phone call.
A smart device can be in communication with the signal processor to receive the at least one physiological parameter and can be in communication with the medical monitoring hub. The smart device can comprise memory storing instructions, and one or more microprocessors configured to execute the instructions to at least compare the at least one physiological parameter to the threshold that is indicative of opioid overdose; determine that the overdose event is occurring or likely to occur based on the comparison; determine that the medical monitoring hub failed to send the at least one activation signal; and send the at least one activation signal to the drug delivery apparatus to dispense at least one dose of the therapeutic drug in response to the determination that that the medical monitoring hub failed to send the at least one activation signal. The memory of the smart device can further store the contact information and the one or more microprocessors of the smart device are can be further configured to notify the contacts of the overdose event.
The drug delivery apparatus can comprise a patch and can include an adhesive layer for adhesion to the user. The at least one physiological parameter can comprise one or more of oxygen saturation, heart rate, respiration rate, pleth variability, and perfusion index. The medical monitoring hub can further comprise an input to receive user input, a speaker, and alarm circuitry, where the one or more computer processors of the medical monitoring hub can be further configured to produce an alarm based on the determination. The method can further comprises increasing volume of the alarm until user input is received.
A method to monitor for indications of opioid overdose can comprise receiving data indicative of at least one physiological parameter of a user that is obtained by a user-wearable sensor; processing the data to provide the at least one physiological parameter; comparing the at least one physiological parameter to a threshold that is indicative of opioid overdose; determining that an overdose event is occurring or likely to occur based on the comparison; and sending at least one activation signal to a drug delivery apparatus to dispense at least one dose of a therapeutic drug based on the determination. The drug delivery apparatus wearable by the user can be configured to deliver one or more doses of the therapeutic drug.
The drug delivery apparatus can comprise a delivery device that includes a dose of a therapeutic drug stored in a reservoir, a drug delivery channel, a dispensing device to dispense the therapeutic drug from the reservoir through the drug delivery channel, and activation circuitry to activate the dispensing device. The drug delivery apparatus can comprise one or more delivery devices. Each drug delivery device can comprise a dose of a therapeutic drug stored in a reservoir, a drug delivery channel, a dispensing device to dispense the therapeutic drug from the reservoir through the drug delivery channel, activation circuitry to activate the dispensing device, and an antenna to receive the at least one activation signal.
The method can further comprise sending two or more activation signals, where each antenna can be tuned to receive a corresponding activation signal at a different frequency, and where each of the two or more activation signals can have the different frequencies to cause corresponding two or more activation circuitry to activate to dispense two or more doses of the therapeutic drug at approximately the same time.
A system to monitor a user for an opioid overdose event can comprise software instructions storable on a memory of a mobile computing device that includes one or more hardware processors, a touchscreen display, and a microphone. The software instructions can cause the one or more hardware processors to receive sounds from the microphone; determine an opioid overdose event is occurring or will soon occur based on the received sounds; present a request for user input on the touchscreen display based on the determination; and transmit wirelessly notifications of the opioid overdose event to one or more recipients based on a failure to receive user input.
The mobile computing device can further comprise a camera, and the one or more hardware processors can be further configured to receive images from the camera, and determine the opioid overdose event is occurring or will soon occur based on the received sounds and images. The one or more hardware processors can be further configured to receive monitoring data from a monitoring service that monitors the user and an environment local to the user; and transmit the notification of the opioid overdose event to the monitoring service. The monitoring service can be a security alarm service.
The monitoring data can include user data associated with a state of the user and environmental data associated with the environment local to the user. The one or more recipients can include friends and family having contact information stored in the memory of the mobile computing device. The one or more recipients can include one or more of a first responder, an emergency service, a local fire station, an ambulance service, a rehabilitation center, an addiction treatment center, and a rideshare network. The notification can include one or more of a text message, a phone call, and an email. The notification can include directions to a location of the mobile computing device.
The one or more hardware processors can further analyze representations of the sounds from the microphone to determine respiratory distress of the user local to the mobile computing device. The one or more hardware processors can further analyze representations of the images from the camera to determine respiratory distress of the user in the images. The one or more hardware processors can further analyze representations of the images from the camera to determine an unconscious state of the user in the images. The one or more processors further can cause the touchscreen display to display care instructions to care for a victim of an opioid overdose.
The mobile computing device can further comprise a speaker and the one or more hardware processors further can cause the speaker to output an audible alarm based on the determination. The one or more hardware processors can further cause the touchscreen display to flash, cause the touchscreen display to display directions to a location of the mobile computing device, or cause a speaker of the mobile computing to provide audible directions to the location of the user.
A system to monitor a user for an opioid overdose event can comprise software instructions storable on a memory of a mobile computing device that includes one or more hardware processors, a touchscreen display, and a camera, the software instructions causing the one or more hardware processors to receive images from the camera; determine an opioid overdose event is occurring or will soon occur based on the received images; present a request for user input on the touchscreen display based on the determination; and transmit wirelessly notifications of the overdose event to one or more recipients based on a failure to receive user input.
The one or more hardware processors can be further configured to receive monitoring data from a monitoring service that monitors the user and an environment local to the user; and transmit the notification of the opioid overdose event to the monitoring service. The monitoring service can be a security alarm service. The monitoring data can include user data associated with a state of the user and environmental data associated with the environment local to the user. The one or more recipients can include friends and family having contact information stored in the memory of the mobile computing device. The one or more recipients can include one or more of a first responder, an emergency service, a local fire station, an ambulance service, a rehabilitation center, an addiction treatment center, and a rideshare network. The notification can include one or more of a text message, a phone call, and an email. The notification can include directions to a location of the mobile computing device.
The one or more hardware processors can further analyze representations the sounds from the microphone to determine respiratory distress of the user local to the mobile computing device. The one or more hardware processors can further analyze representations of the images from the camera to determine respiratory distress of the user in the images. The one or more hardware processors can further analyze representations of the images from the camera to determine an unconscious state of the user in the images. The one or more processors further can cause the touchscreen display to display care instructions to care for a victim of an opioid overdose. The mobile computing device can further comprise a speaker and the one or more hardware processors further can cause the speaker to output an audible alarm based on the determination. The one or more hardware processors can further cause the touchscreen display to flash, cause the touchscreen display to display directions to a location of the mobile computing device, or cause a speaker of the mobile computing to provide audible directions to the location of the user.
A system to monitor a user for an opioid overdose event can comprise one or more sensors configured to sense indications of an overdose condition of a user from an environment local to the user; and a mobile computing device comprising a touchscreen display, memory storing software instructions, and one or more hardware processors configured to execute the software instructions to at least receive the sensed indications from the one or more sensors; determine an opioid overdose event is occurring or will soon occur based on the received indications; present a request for user input on the touchscreen display based on the determination; and transmit wirelessly notifications of the overdose event to one or more recipients based on a failure to receive user input.
The one or more hardware processors can be further configured to receive monitoring data from a monitoring service that monitors the user and an environment local to the user; and transmit the notification of the opioid overdose event to the monitoring service. The monitoring service is a security alarm service. The monitoring data can include user data associated with a state of the user and environmental data associated with the environment local to the user. The one or more recipients can include friends and family having contact information stored in the memory of the mobile computing device. The one or more recipients can include one or more of a first responder, an emergency service, a local fire station, an ambulance service, a rehabilitation center, an addiction treatment center, and a rideshare network. The notification can include one or more of a text message, a phone call, and an email. The notification can include directions to a location of the mobile computing device.
The one or more hardware processors can further analyze representations of the sounds from the microphone to determine respiratory distress of the user local to the mobile computing device. The one or more hardware processors can further analyze representations of the images from the camera to determine respiratory distress of the user in the images. The one or more hardware processors can further analyze representations of the images from the camera to determine an unconscious state of the user in the images. The one or more processors further can cause the touchscreen display to display care instructions to care for a victim of an opioid overdose. The mobile computing device can further comprise a speaker and the one or more hardware processors further can cause the speaker to output an audible alarm based on the determination. The one or more hardware processors can further cause the touchscreen display to flash, cause the touchscreen display to display directions to a location of the mobile computing device, or cause a speaker of the mobile computing to provide audible directions to the location of the user.
A method to monitor a user for an opioid overdose event can comprise receiving sounds from a microphone of a mobile computing device; determining, with one or more hardware processors of the mobile computing device, an opioid overdose event is occurring or will soon occur based on the received sounds; presenting, with one or more hardware processors, a request for user input on a touchscreen display of the mobile computing device, the request based on the determination; and transmitting wirelessly, with the mobile computing device, notifications of the overdose event to one or more recipients based on a failure to receive user input.
The method can further comprise receiving images from a camera of the mobile computing device; and determining, with the one or more hardware processors of the mobile computing device, the opioid overdose event is occurring or will soon occur based on the received sounds and images. The method can further comprise receive monitoring data from a monitoring service that monitors the user and an environment local to the user; and transmit the notification of the opioid overdose event to the monitoring service. The monitoring service is a security alarm service. The monitoring data can include user data associated with a state of the user and environmental data associated with the environment local to the user. The one or more recipients can include friends and family having contact information stored in the memory of the mobile computing device. The one or more recipients can include one or more of a first responder, an emergency service, a local fire station, an ambulance service, a rehabilitation center, an addiction treatment center, and a rideshare network. The notification can include one or more of a text message, a phone call, and an email. The notification can include directions to a location of the mobile computing device.
The method can further comprise analyzing representations of the sounds from the microphone to determine respiratory distress of the user local to the mobile computing device. The method can further comprise analyzing representations of the images from the camera to determine respiratory distress of the user in the images. The method can further comprise analyzing representations of the images from the camera to determine an unconscious state of the user in the images. The method can further comprise causing the touchscreen display to display care instructions to care for a victim of an opioid overdose. The method can further comprise outputting, from the mobile computing device, an audible alarm based on the determination.
The method can further comprise causing the touchscreen display to flash, cause the touchscreen display to display directions to a location of the mobile computing device, or cause a speaker of the mobile computing to provide audible directions to the location of the user.
A method to monitor a user for an opioid overdose event can further comprise receiving images from a camera of a mobile computing device; determining, with one or more hardware processors of the mobile computing device, an opioid overdose event is occurring or will soon occur based on the received images; presenting, with one or more hardware processors, a request for user input on a touchscreen display of the mobile computing device, the request based on the determination; and transmitting wirelessly, with the mobile computing device, notifications of the overdose event to one or more recipients based on a failure to receive user input.
The method can further comprise receiving monitoring data from a monitoring service that monitors the user and an environment local to the user; and transmitting the notification of the opioid overdose event to the monitoring service. The monitoring service can be a security alarm service. The monitoring data can include user data associated with a state of the user and environmental data associated with the environment local to the user. The one or more recipients can include friends and family having contact information stored in the memory of the mobile computing device. The one or more recipients can include one or more of a first responder, an emergency service, a local fire station, an ambulance service, a rehabilitation center, an addiction treatment center, and a rideshare network. The notification can include one or more of a text message, a phone call, and an email. The notification can include directions to a location of the mobile computing device. The method can further comprise analyzing representations the sounds from the microphone to determine respiratory distress of the user local to the mobile computing device.
A method to monitor a user for an opioid overdose event can comprise receiving sensed indications of an overdose condition of a user from one or more sensors configured to sense an environment local to the user; determine an opioid overdose event is occurring or will soon occur based on the received indications; present a request for user input on the touchscreen display based on the determination; and transmit wirelessly notifications of the overdose event to one or more recipients based on a failure to receive user input.
The method can further comprise receiving monitoring data from a monitoring service that monitors the user and an environment local to the user; and transmitting the notification of the opioid overdose event to the monitoring service. The monitoring service can be a security alarm service. The monitoring data can include user data associated with a state of the user and environmental data associated with the environment local to the user. The method can further comprise analyzing representations of the images from the camera to determine respiratory distress of the user in the images.
The method can further comprise analyzing representations of the images from the camera to determine an unconscious state of the user in the images. The method can further comprise causing the touchscreen display to display care instructions to care for a victim of an opioid overdose. The method can further comprise outputting, from the mobile computing device, an audible alarm based on the determination.
A system to monitor for indications of opioid overdose event can comprise software instructions storable in memory of a first mobile computing device. The software instructions executable by one or more hardware processors of the first mobile computing device can cause the one or more hardware processors to continuously receive data indicative of one or more physiological parameters of a first user that is being monitored by one or more sensors; continuously compare each of the one or more physiological parameters with a corresponding threshold; determine an opioid overdose event is occurring or will soon occur based on the comparisons; trigger an alarm on the first mobile computing device based on the determination; and notify a second user of the alarm by causing a display of a second mobile computing device associated with the second user to display a status of an alarming physiological parameter of the first user.
The one or more hardware processors can further cause a display of the first mobile computing device to continuously update graphical representations of the one or more physiological parameters in response to the continuously received data. The one or more hardware processors can further display a user-selectable input to view additional information associated with the first user.
Selecting the user-selectable input can cause the display of the second mobile computing device to display one or more of trends and current value of the alarming physiological parameter. Selecting the user-selectable input can cause the display of the second mobile computing device to display a location of the first mobile computing device on a map. Selecting the user-selectable input can cause the display of the second mobile computing device to display a time of an initial alarm. Selecting the user-selectable input can cause the display of the second mobile computing device to provide access to directions to the first mobile computing device from a location of the second mobile computing device. Selecting the user-selectable input can cause the display of the second mobile computing device to provide access to call the first mobile computing device.
The one or more physiological parameters can be represented as dials on the display. The one or more physiological parameters can include one or more of oxygen saturation, heart rate, respiration rate, pleth variability, perfusion index, and respiratory effort index. The alarm can be an audible and visual alarm. Each of the corresponding thresholds can be adjustable based on characteristics of the first user to inhibit false-positive alarms.
The one or more hardware processors can further transmit indications of the one or more physiological parameters to a remote server. The one or more hardware processors can further transmit indications of the one or more physiological parameters to a medical monitoring hub for storage in memory of the medical monitoring hub. The one or more hardware processors can communicate wirelessly with a local Internet of Things connected device to receive additional data for use in the determination of the opioid overdose event. The one or more hardware processors can further notify emergency services of the alarm. The first and second mobile computing devices can be smart phones.
A method to monitor for indications of an opioid overdose event can comprise continuously receiving, with a first mobile computing device, data indicative of one or more physiological parameters of a first user that is being actively monitored by one or more sensors; continuously comparing, with the first mobile computing device, each of the one or more physiological parameters with a corresponding threshold; determining, with the first mobile computing device, an opioid overdose event is occurring or will soon occur based on the comparisons; triggering, with the first mobile computing device, an alarm on the first mobile computing device based on the determination; and notifying, with the first mobile computing device, a second user of the alarm by causing a display of a second mobile computing device associated with the second user to display a status of an alarming physiological parameters of the first user.
The method can further comprise causing a display of the first mobile computing device to continuously update graphical representations of the one or more physiological parameters in response to the continuously received data. The method can further comprising displaying a user-selectable input to view additional information associated with the first user.
Selecting the user-selectable input can cause the display of the second mobile computing device to display one or more of trends and current value of the alarming physiological parameter. Selecting the user-selectable input can cause the display of the second mobile computing device to display a location of the first mobile computing device on a map. Selecting the user-selectable input can cause the display of the second mobile computing device to display a time of an initial alarm. Selecting the user-selectable input can cause the display of the second mobile computing device to provide access to directions to the first mobile computing device from a location of the second mobile computing device. Selecting the user-selectable input can cause the display of the second mobile computing device to provide access to call the first mobile computing device.
The one or more physiological parameters can be represented as dials on the display. The one or more physiological parameters can include one or more of oxygen saturation, heart rate, respiration rate, pleth variability, perfusion index, and respiratory effort index. The alarm can be an audible and visual alarm. Each of the corresponding thresholds can be adjustable based on characteristics of the first user to inhibit false-positive alarms.
The method can further comprise transmitting indications of the one or more physiological parameters to a remote server. The method can further comprise transmitting indications of the one or more physiological parameters to a medical monitoring hub for storage in memory of the medical monitoring hub. The method can further comprise communicating wirelessly with a local Internet of Things connected device to receive additional data for use in the determination of the opioid overdose event. The method can further comprise notifying emergency services of the alarm. The first and second mobile computing devices can be smart phones.
For purposes of summarizing the disclosure, certain aspects, advantages and novel features are discussed herein. It is to be understood that not necessarily all such aspects, advantages or features will be embodied in any particular embodiment of the invention, and an artisan would recognize from the disclosure herein a myriad of combinations of such aspects, advantages or features.
Various embodiments will be described hereinafter with reference to the accompanying drawings. The drawings and the associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims. In the drawings, similar elements have similar reference numerals.
Although certain embodiments and examples are described below, this disclosure extends beyond the specifically disclosed embodiments and/or uses and obvious modifications and equivalents thereof. Thus, it is intended that the scope of this disclosure should not be limited by any particular embodiments described below.
Overview
An application for a mobile computing device that is used in conjunction with a physiological parameter monitoring assembly to detect physiological parameters of an opioid user can comprise determining a physiological condition of the opioid user based at least in part on the physiological parameters, and providing notifications based at least in part on the physiological condition of the opioid user. The physiological parameter monitoring assembly can be a pulse oximeter that includes a sensor and a signal processing device. Examples of physiological parameters that can be monitored are peripheral oxygen saturation (SpO2), respiration, and perfusion index (PI). The application can determine the physiological condition of the user based on the SpO2 alone, respiration alone, PI alone, a combination of the SpO2 and respiration, a combination of the SpO2 and PI, a combination of the respiration and the PI, or a combination of the SpO2, respiration, and PI.
The application can request user input and determine the physiological condition of the user based at least in part on the received user input and the physiological parameters from the pulse oximeter. The determination of the user's condition can be based on the user input and one or more of peripheral oxygen saturation (SpO2), respiration, and perfusion index (PI). The application can learn, based at least in part on stored physiological parameters, trends in user's the physiological reaction to opioid use to better anticipate overdose events of the user.
The application can notify one or more of caregivers, loved ones, friends, and first responders of an overdose event. The application can provide “everything OK” notifications upon request or periodically to concerned family and friends. The application can provide detailed care instructions to first responders. The application can provide the location of the user, the location of the closest medication to reverse the effects of an opioid overdose, or the location of the closest medical personnel. The application can provide one or more of visual, audible, and sensory (vibration) alerts to the user with increasing frequency and intensity to the user.
An application for a mobile computing device that is used in conjunction with a sensor and a signal processing device to detect abnormally low blood oxygen saturation that is indicative of an overdose event in a user can comprise triggering an alarm, and notifying others of the overdose event. This increases the likelihood that opioid users, their immediate personal networks, and first responders are able to identify and react to an overdose by administrating medication to reverse the effects of the overdose. Such medication can be considered an opioid receptor antagonist or a partial inverse agonist. Naloxone or Narcan® is a medication that reverses the effect of an opioid overdose and is an opioid receptor antagonist. Buprenorphine or Subutex® is an opioid used to treat opioid addiction. Buprenorphine combined with naloxone or Suboxone® is a medication that may also be used to reverse the effect of an opioid overdose. Other example medications are naltrexone, nalorphine, and levallorphan. Administration can be accomplished by intravenous injection, intramuscular injection, and intranasally, where a liquid form of the medication is sprayed into the user's nostrils. Administration of the medication can also occur via an endotracheal tube, sublingually, where a gel or tablet of the medication is applied under the tongue, and transdermally, where the medication can be a gel applied directly to the skin or within a transdermal patch applied to the skin.
A system to monitor a user for an opioid overdose condition can comprise a sensor configured to monitor one or more physiological parameters of a user, a signal processing device configured to receive raw data representing the monitored one or more physiological parameters and to provide filtered parameter data; and a mobile computing device configured to receive the one or more physiological parameters from the signal processing device. The mobile computing device comprises a user interface, a display, network connectivity, memory storing an application as executable code, and one or more hardware processors. The application monitors the physiological parameters to determine a condition of the user and provides notifications to the user, to a crowd-sourced community of friends, family, and other opioid users that have also downloaded the application onto their computing devices, and to emergency providers and medical care personnel.
Home pulse oximetry monitoring systems for opioid users can include a pulse oximeter, such as a Masimo Rad-97 Pulse CO-Oximeter®, for example, and sensors, such as Masimo LNCS® adhesive sensors and the like, to detect blood oxygen levels and provide alerts and alarms when the opioid user's blood oxygen level drops below a threshold. The home monitoring system can provide alarm notifications that can alert a family member, remote caregiver, and a first responder, for example, to awaken the opioid user and to administer the antidote for an opioid overdose, such as an opioid receptor antagonist.
The mobile computing device can be configured to receive the filtered parameter data from the signal processing device; display representations of the filtered parameter data on the display, where the filtered parameter data includes at least oxygen saturation data for the oxygen level in the blood of the user; compare a current oxygen saturation value to a minimum oxygen saturation level; trigger an alarm when the current oxygen saturation value is below the minimum oxygen saturation level; and provide notifications over a network to another when the current oxygen saturation value is below the minimum oxygen saturation level.
The display can display the representations of the filtered parameter data as dials indicating acceptable and acceptable ranges. The filtered parameter data can include one or more of heart rate data, respiration rate data, pleth variability data, perfusion index data, and respiratory effort index data. The application can provide notifications to the user and can provide notifications to others. The notification can be one or more of a text message, an email, and a phone call. The notification can include a current value of oxygen saturation and a graph indicting a trend of the oxygen saturation levels. The notification can further include one or more of a phone number of the user, a location of the user, directions to the location of the user, a closest location of naloxone or other medication used to reverse the effects of an opioid overdose. The notification can be an automatic call to emergency responders.
A system to monitor a user for an opioid overdose condition can comprise one or more computing devices associated with an opioid overdose monitoring service. The opioid overdose monitoring service can be configured to identify opioid monitoring information from at least one physiological monitoring system associated with a user, where the opioid monitoring information comprises one of an overdose alert and a non-distress status, retrieve over a network notification information associated with the user, where the notification information includes first contact information associated with the overdose alert and second contact information associated with the non-distress status, send an overdose notification using the first contact information in response to the opioid monitoring information that indicates the overdose alert, and send a non-distress notification using the second contact information in response to the opioid monitoring information that indicates the non-distress status.
The system can further comprise a physiological monitoring system comprising a sensor configured to monitor one or more physiological parameters of the user and a signal processing board configured to receive raw data representing the monitored one or more physiological parameters and to provide filtered parameter data, and a mobile computing device comprising a display, network connectivity, memory storing executable code, and one or more hardware processors. The mobile computing device can be configured to receive the filtered parameter data from the signal processing board, display representations of the filtered parameter data on the display, where the filtered parameter data includes at least oxygen saturation data for the oxygen level in the blood of the user, compare a current oxygen saturation value to a minimum oxygen saturation level, and trigger an alarm when the current oxygen saturation value is below the minimum oxygen saturation level.
The mobile computing device can be configured to receive the filtered parameter data from the signal processing board, generate the opioid monitoring information based on the filtered parameter data, and send the opioid monitoring information over a network to the opioid overdose monitoring service. The filtered parameter data can include one or more of a current oxygen saturation value, heart rate data, respiration rate data, pleth variability data, perfusion index data, and respiratory effort index data. The overdose and non-distress notifications can comprise one or more of a text message, an email, and a phone call. The overdose and non-distress notifications can include a current value of oxygen saturation and a graph indicting a trend of the oxygen saturation levels. The overdose notification can comprise one or more of a phone number of the user, a location of the user, directions to the location of the user, a closest location of naloxone or other medication used to reverse the effects of an opioid overdose. The overdose notification can automatically calls emergency responders. The network can be the Internet.
A kit for monitoring for an opioid overdose event can comprise a sensor to sensor physiological parameters and a medical monitoring hub device to receive indications of the sensed physiological parameters and to receive an indication of an opioid overdose event. The kit can further comprise a delivery device to deliver medication in response to the indication of the opioid overdose event. The delivery device can automatically administers an opioid receptor antagonist in response to the indication of an opioid overdose event. The delivery device can comprise a patch that includes a reservoir with the medication, a needle, and a battery. The hub device can comprise memory for storage of the indication of the sensed physiological parameters. The hub device can receive and store data from monitoring devices other than the sensor. The data from the monitoring devices can comprise data associated with a well-being of a user. The kit may be available without a prescription.
Instrumentation-Sensor and Signal Processing Device
The sensor 102 and the signal processing device 110 can comprise a pulse oximeter. Pulse oximetry is a noninvasive method for monitoring a person's oxygen saturation. The sensor 102 is placed on the user's body and passes two wavelengths of light through the body part to a photodetector. The sensor 102 can provide raw data 104 to the signal processing device 110, which determines the absorbance's of the light due to pulsating arterial blood. The pulse oximeter generates a blood-volume plethysmograph waveform from which oxygen saturation of arterial blood, pulse rate, and perfusion index, among other physiological parameters, can be determined, and provides physiological parameters 118 to the mobile computing device 120.
The pulse oximeter can be transmissive, where the sensor 102 is placed across a thin part of the user's body, such as a fingertip or earlobe, for example, or reflective, where the sensor 102 can be placed on the user's forehead, foot, or chest, for example.
The sensor 102 and the signal processing device 110 can be packaged together. The sensor 102 can be not packaged with the signal processing device 110 and communicates wirelessly or via a cable with the signal processing device 110.
Examples of pulse oximeters are the MIGHTYSAT RX fingertip pulse Oximeter®, the Rad-57® handheld pulse CO-oximeter, and the Rainbow® CO-oximeter, all by Masimo Corporation, Irvine, Calif., which are capable of being secured to a digit, such as a finger.
Because opioid users may want to be discrete when monitoring opioid use for indications of an overdose event, sensors 102 that are not visible may provide additional confidentiality for the user. The sensor 102 can be applied to a toe and the signal processing device 110 can comprise an ankle brace. The sensor 102 can be a ring on the user's finger or a bracelet on the user's wrist, and the signal processing device 110 can be within an arm band hidden under the user's sleeve. The sensor 102 or the sensor 102 and the signal processing device 110 can be integrated into a fitness device worn on the user's wrist. Such pulse oximeters can be reflective or transmissive. The sensor 102 can be an ear sensor that is not readily visible.
Other varieties of sensors 102 can be used, for example adhesive sensors, combination reusable/disposable sensors, soft and/or flexible wrap sensors, infant or pediatric sensors, multisite sensors, or sensors shaped for measurement at a tissue site such as an ear.
Other sensors 102 can be used to measure physiological parameters of the user. For example, a modulated physiological sensor can be a noninvasive device responsive to a physiological reaction of the user to an internal or external perturbation that propagates to a skin surface area. The modulated physiological sensor has a detector, such as an accelerometer, configured to generate a signal responsive to the physiological reaction. A modulator varies the coupling of the detector to the skin so as to at least intermittently maximize the detector signal. A sensor processor controls the modulator and receives an effectively amplified detector signal, which is processed to calculate a physiological parameter indicative of the physiological reaction. A modulated physiological sensor and corresponding sensor processor are described in U.S. Publication No. 2013/0046204 to Lamego et al., filed Feb. 21, 2013, titled “MODULATED PHYSIOLOGICAL SENSOR” and assigned to Masimo Corporation, Irvine, Calif., which is hereby incorporated by reference herein.
The sensor 102 can include an electroencephalograph (“EEG”) that can be configured to measure electrical activity along the scalp. The sensor 102 can include a capnometer or capnograph that can be configured to measure components of expired breath.
An acoustic sensor 102 can be used to determine the user's respiration rate. An acoustic sensor utilizing a piezoelectric device attached to the neck is capable of detecting sound waves due to vibrations in the trachea due to the inflow and outflow of air between the lungs and the nose and mouth. The sensor outputs a modulated sound wave envelope that can be demodulated so as to derive respiration rate. An acoustic respiration rate sensor and corresponding sensor processor is described in U.S. Publication No. 2011/0125060 to Telfort et al., filed Oct. 14, 2010, titled “ACOUSTIC RESPIRATORY MONITORING SYSTEMS AND METHODS” and assigned to Masimo Corporation, Irvine, Calif., which is hereby incorporated by reference herein.
The mobile computing device 120 can include an accelerometer that is configured to detect motion of the mobile computing device 120. When the user holds the mobile computing device 120 or attaches the mobile computing device 120 to his clothing in such a way that the accelerometer detects motion of the user, then the accelerometer can be used to detect lack of motion of the user. The lack of user motion can be used to determine the user's condition, as described below.
When the user holds the mobile computing device 120, the accelerometer can sense vibrations from the user indicative of the user's heart rate. A lack of vibrations sensed by the accelerometer can indicate no heart rate and reduced occurrences of vibrations sensed by the accelerometer can indicate cardiac distress. The indications of cardiac activity sensed by the accelerometer in the mobile computing device can be used to determine the user's condition, as described below.
The sensor 102 can be a centroid patch worn by the user that includes an accelerometer. Data indicative of the movement of the accelerometer can be transmitted wirelessly to the mobile computing device 120. Based on movement detected by the accelerometer, the application detects the respiration rate of the user. An oxygen sensor configured to monitor the user's breath can wirelessly transmit an indication of the oxygen present in the user's exhaled breath.
The physiological sensor 102 and the mobile computing device 120 can be connected via a cable or cables and the signal processing device 110 can be connected between the sensor 102 and the mobile computing device 120 to conduct signal processing of the raw data 104 before the physiological parameters 118 are transmitted to the mobile computing device 120. A mobile physiological parameter monitoring system is described in U.S. Pat. No. 9,887,650 to Muhsin et al., issued on Jan. 30, 2018, titled “PHYSIOLOGICAL MONITOR WITH MOBILE COMPUTING DEVICE CONNECTIVITY”, and assigned to Masimo Corporation, Irvine, Calif., which is hereby incorporated by reference herein.
In various oximeter examples, the sensor 102 provides data 104 in the form of an output signal indicative of an amount of attenuation of predetermined wavelengths (ranges of wavelengths) of light by body tissues, such as, for example, a digit, portions of the nose or ear, a foot, or the like. The predetermined wavelengths often correspond to specific physiological parameter data desired, including for example, blood oxygen information such as oxygen content (SpOC), oxygen saturation (SpO2), blood glucose, total hemoglobin (SbHb), methemoglobin (SbMet), carboxyhemoglobin (SpCO), bulk tissue property measurements, water content, pH, blood pressure, respiration related information, cardiac information, perfusion index (PI), pleth variability indices (PVI), or the like, which can be used by the mobile computing device 120 to determine the condition of the user. Sensor data 104 can provide information regarding physiological parameters 118 such as EEG, ECG, heart beats per minute, acoustic respiration rate (RRa), breaths per minute, end-tidal carbon dioxide (EtCO2), respiratory effort index, return of spontaneous circulation (ROSC), or the like, which can be used to determine the physiological condition of the user.
Referring to
The sensor data 104 can be corrupted by noise due to patient movement, electromagnetic interference, or ambient light, for example. The physiological parameter monitoring system 100 can apply noise filtering and signal processing to provide the physiological parameters 118 for analysis and display on the mobile computing device 120. Such complex processing techniques can exceed the processing capabilities of the mobile computing device 120, and therefore the signal processing device 110 can handle signal processing of the raw sensor data 104 and transmit the processed physiological parameters 118 to the mobile computing device 120.
In the context of pulse oximetry, the signal processing device 110 can use adaptive filter technology to separate an arterial signal, detected by a pulse oximeter sensor 102, from the non-arterial noise (e.g. venous blood movement during motion). During routine patient motions (shivering, waving, tapping, etc.), the resulting noise can be quite substantial and can easily overwhelm a conventional ratio based oximetry system. This can provide accurate blood oxygenation measurements even during patient motion, low perfusion, intense ambient light, and electrocautery interference. Accordingly, false alarms can be substantially eliminated without sacrificing true alarms.
The signal processing device 110 can transmit the physiological parameters 118 wirelessly, using Bluetooth®, near field communication protocols, Wi-Fi, and the like to the mobile computing device 120, or the signal processing device 110 can transmit the physiological parameters 118 to the mobile computing device 120 through a cable.
Instrumentation-Mobile Computing Device
Any mobile computing device 120 that is compatible with the physiological parameter assembly that includes the sensor 102 and the signal processing device 110 can be used. A compatible mobile computing device can be one of a wide range of mobile devices such as, but not limited to a mobile communications device (such as a smartphone), laptop, tablet computer, netbook, PDA, media player, mobile game console, wristwatch, wearable computing device, or other microprocessor based device configured to interface with the signal processing device 110 and provide notifications based at least in part on the monitored physiological parameters 118.
Referring to
The mobile computing device 120 can include a user interface 126 that can receive user input. The user interface 126 can include buttons, a key pad, the touch sensitive technologies of the display screen 122, and other user input mechanisms typically found on the various example mobile computing devices 120.
The mobile computing device 120 can also include data storage 124, which can be configured for storage of the physiological parameters 118 and parameter history data and/or software applications that monitor the physiological parameters for an overdose indication and provide notifications. The storage 124 can be physical storage of the mobile computing device 120, and the storage 124 can be remote storage, such as on a server or servers of a data hosting service.
The mobile computing device 120 can also include a network connectivity feature 128 that provides network connection capabilities such as one or more of a cellular network, satellite network, Bluetooth, ZigBee, wireless network connection such as Wi-Fi or the like, and a wired network connection. The mobile computing device 120 can also include a data transfer port.
Application Functionality Overview
The mobile computing device 120 can include software such as an application 130 configured to manage the physiological parameters 118 from the physiological parameter monitoring device 110. The application functionality can include trend analysis, current measurement information, alarms associated with above/below threshold readings, reminders to take measurement data at certain times or cycles, display customization, iconic data such as hearts beating, color coordination, bar graphs, gas bars, charts, graphs, or the like, all usable by a caregiver or application user to provide medical monitoring of specified physiological parameters. The display 122 can display the physiological parameters 118 as numerical values, graphs, charts, dials and the like.
The application 130 via the mobile computing device 120 can also alert the user and/or person(s) designated by the user to an abnormal data reading. For example, an abnormally low blood oxygen saturation reading can cause the mobile computing device 120 to buzz, vibrate or otherwise notify the user of an abnormal reading, and to transmit a notification or alert to the user, the designated person(s) or medical personnel to a network via the network connectivity 128.
In addition, the application 130 includes one or more processes to monitor the physiological parameters 118 for the condition of the user, and in particular for signs of an opioid overdose. The application 130 can be set up by the user or a caregiver to notify another of the overdose event. This increases the likelihood that the opioid user, their immediate personal networks, and first responders are able to identify and react to an overdose by administrating medication used to reverse the effects of an opioid overdose, such as naloxone. Naloxone is an overdose-reversal drug. In some states, people who are or who know someone at risk for opioid overdose can go to a pharmacy or community-based program to get trained on naloxone administration and receive naloxone by “standing order,” which means a patient-specific prescription is not required. When administered in time, naloxone can restore an overdose victim's breathing long enough for trained medical assistance to arrive. In some instances, other overdose reversal drugs can be used, such as buprenorphine, and combination of buprenorphine and naloxone, and the like.
The application 130 can include processes and information to monitor and provide care to opioid users, such as, but not limited to an overdose detection process 131 configured to determine the condition of the user and whether medical care is indicated based at least on the physiological parameters 118, an alert management process 132 configured to manage alerts to the user and others in the user's network based at least in part on condition of the user, and information for the care/treatment for opioid use, such as a critical care instruction video 133.
Opioid Overdose Monitoring
At block 210, the signal processing device 110 receives the raw data 104 from the sensor 102, processes the raw data 104 to provide one or more parameters 118 to the mobile computing device 120. In the case of pulse oximetry, the signal processing device 110 generates a blood-volume plethysmograph waveform from which at least the peripheral oxygen saturation of arterial blood (SpO2), respiration, pulse rate, and perfusion index (PI) may be determined. Other physiological parameters that may be determined are, for example, oxygen content (SpOC), blood glucose, total hemoglobin (SbHb), methemoglobin (SbMet), carboxyhemoglobin (SpCO), bulk tissue property measurements, water content, pH, blood pressure, cardiac information, and pleth variability indices (PVI). Sensor data 104 can provide information regarding physiological parameters 118 such as, for example, EEG, ECG, heart beats per minute, acoustic respiration rate (RRa), breaths per minute, end-tidal carbon dioxide (EtCO2), respiratory effort index, and return of spontaneous circulation (ROSC).
User Input
At block 215, the application 130 via the mobile computing device 120 can query the user and receive user input. The mobile computing device 120 can present questions on the display 122 and the user can reply using the user interface 126. For example, the user can be asked for the information on the prescription label, the dosage and/or frequency of the opioid being consumed and any other drugs the user is consuming. The mobile computing device 120 can ask the user to input his weight, age, and other physical attributes that may be factors in the user's reaction to the opioid and dosages of the medication, such as naloxone and the like, used to reverse the effects of an overdose. The mobile computing device 120 can ask whether the user is OK or in need of assistance. A response from the user can indicate that the user is conscious and not overdosed. The application 130 can ask the user for a response when the analysis of the parameters 118 indicates an overdose event, and if a response is received, indicating the user is conscious and not overdosed, the application 130 can refine the threshold used to determine an overdose event. The mobile computing device 120 can confirm the users name and location.
Trends
At block 220, the application 130 can develop trends in the user's opioid usage using the physiological parameters 118 from past monitoring stored in the storage 124 as well as user input relating to weight, age, dosage, frequency, and additional drugs being consumed. The trends can be based on the parameters 118 and the user input, if any is received.
For example, opioid users that are also marijuana users can develop a greater tolerance for opioids. Further, opioids initially cause the perfusion index to increase due to vasodilation, then to decrease due to vasoconstriction. The increase and decrease of the perfusion index creates a perfusion profile. A user with a greater tolerance to opioids can have a different perfusion profile than a user that does not use marijuana in conjunction with opioids.
The application 130 can use the user input, if available, and stored physiological parameters, such as the perfusion profile, for example, and current physiological parameters to develop trends in the user's opioid usage and/or tolerance for opioids that can more accurately anticipate an overdose event. The application 130 can use past occurrences of “near misses” to further refine the conditions that may foreshadow an overdose event. A “near miss” is an event that provided indications of an overdose, such as an indication of respiration below a threshold, but did not result in an overdose event. The opioid dosage associated with a near miss can provide an indication of the user's tolerance to opioids and can be used by the application 130 to refine the determination of an imminent or occurring opioid overdose event.
By using the history of the physiological parameters 118 including the near-misses, and the user input, if available, the application 130 can learn which combination of events and parameter values indicate an overdose event may be imminent. Because time is of the essence in administrating medication, such as naloxone and the like, to reverse or reduce the effects of an overdose to an overdose victim, it is desirable to err in over-reporting, but too many false-positives of opioid notifications may desensitize responders. It is important that the application 130 learn the specific triggers for a specific user to increase accuracy in determining an overdose event for the specific user. The application 130 can learn the conditions leading up to an overdose event and refine its algorithm in order to notify others when help is needed and to discriminate against false-positive events.
The user's tolerance, as well as the user's physical attributes, such as weight and age, can be used by the application 130 to refine the quantity of medication that reverses or reduces the effects of an overdose, such as naloxone and the like, that should be administered to revive the user in an overdose event. The application 130 can monitor doses of the medication and report the dosages to clinicians who can determine whether the dosage is too high or too low.
The process 200 uses one or more of the user input, current physiological parameters, stored physiological parameters, “near miss” events, overdose events, to refine the indications of an overdose event so as to be able to more accurately determine the occurrence of an overdose event without notifying others of an overdose event that turns out to be false. Because time is of the essence in responding to an overdose victim, the application 130 may err on the side of over notification, but can learn the triggers for the specific user to avoid “crying wolf”, which may result in others ignoring the notifications.
Data Analysis
At block 225, the application 130 determines the condition of the user based on one or more of the physiological parameters, user input, and trends. For example, the application 130 can compare the physiological parameters 118 against a threshold to determine is an overdose event is occurring or will soon occur. For example, opioids depress the user's breathing. If the one or more of the oxygen saturation, breaths per minute, perfusion index and respiratory effort index indicate respiratory failure but being less that a threshold, the application may determine that an overdose event has occurred. The threshold can be a predetermined threshold that is adjusted as the application 130 learns the overdose triggers associated with the user. As the application 130 develops the trends, the application can refine the thresholds for one or more of the physiological parameters 118.
The application 130 can use the user's perfusion index to determine the likelihood of an overdose event. For example, opioids initially cause the perfusion index to increase due to vasodilation, then to decrease due to vasoconstriction. This can be an identifiable perfusion profile that anticipates an overdose event.
The application 130 can use one or more physiological parameters 118 to determine the condition of the user. The application 130 can use one or more of the perfusion index (PI), respiration, and peripheral oxygen saturation (SpO2) to determine the condition of the user. For example, the application 130 can use, but is not limited to, each of the perfusion index (PI), respiration, and peripheral oxygen saturation (SpO2) alone; a combination of the PI, respiration, and SpO2 together; a combination of PI and respiration; a combination of PI and SpO2; or a combination of respiration and SpO2 to determine the condition of the user. The analysis of the physiological parameters 118 may show that the physiological parameters are within normal ranges and the user is not in need of assistance or the analysis may indicate that an overdose event is imminent, is occurring, or has occurred.
Other physiological parameters 118 can be analyzed individually or in other combinations can be analyzed to determine whether the physiological parameters 118 of the user are within normal ranges or whether an overdose event is imminent, is occurring, or has occurred.
The application 130 can query the user to determine the condition of the user. No response from the user can indicate that the user is unconscious and can trigger an overdose event notification or alarm. As indicated above, a response from the user can indicate that the user is conscious and the information can be used by the application 130 to refine the changes in the user's physiological parameters 118 that indicate an opioid overdose is occurring or will occur soon.
As described above, the mobile computing device 120 can include an accelerometer that can detect user motion. A lack of user motion sensed by the accelerometer can indicate that the user in unconscious and can trigger an overdose event notification or alarm. Motion sensed by the accelerometer can indicate that the user is conscious and the information can be used by the application 130 to refine the changes in the user's physiological parameters 118 that indicate an opioid overdose is occurring or will occur soon.
As described above, the mobile computing device 120 can include an accelerometer that can sense vibrations from the user indicative of the user's heart rate. A lack of vibrations sensed by the accelerometer can indicate no heart rate and reduced occurrences of vibrations sensed by the accelerometer can indicate cardiac distress, which can trigger an overdose event notification or alarm. Heart rate within normal parameters can indicate that the user is not in need of assistance due to an overdose event.
At block 230, the application 130 can determine whether care is useful based on the condition of the user. If care is indicated, such that the physiological parameters indicate depressed respiration, but not at a life-threatening level, the application moves to block 235. At block 235, the application 130 queries the user. If a response is received, the process 200 moves to the END block. A response indicates that the user is conscious and not in need if immediate aid.
If, at block 230, the application 130 determines that care is required because the evaluation of the physiological parameters 118 indicate a life-threatening condition, the process 200 moves to block 240. In addition, if no response is received from the user query at block 235, the process 200 moves to block 240.
Notifications
At block 240, the application 130 provides notifications based at least in part of the condition of the user. For example, the application 130 can display on the display 122 the user's physiological parameters, such as one or more of oxygen saturation, heart beats per minute, breaths-per-minute, pleth variability, perfusion index, and respiratory effort. The physiological parameters 118 can be displayed as charts, graphs, bar charts, numerical values, and the like. The application 130 can display trends in the physiological parameters 118.
The application 130 can provide notifications to selected friends indicating that there are no overdose conditions. The “everything is OK” notifications can be sent periodically or upon request. The “everything is OK” notifications can be sent during known exposure times. For example, the “everything is OK” notifications can be sent every 30 minutes from 6:00 PM when the user typically returns from work, to 11:00 PM when the user typically goes to sleep.
The application 130 can also report “near misses” to the caregiver. As described above, a “near miss” is an event that provided indications of an overdose, such as an indication of respiration below a threshold, but did not result in an overdose event.
Once the application 130 has determined that an overdose condition is imminent, is occurring, or has occurred, the application 130 can provide notification of the overdose to selected family, friends, caregivers, clinicians, and medical personnel. The notification can be sent to a crowd sourced community of users, friends, and medical personnel that look out for one another. The application 130 can provide the location of the user and/or directions to the user's location. The notification can include the location of the closest medical care and/or the location of the closest medication that reduces or reverses the effects of an overdose. Examples of such medications are, but not limited to, naloxone, buprenorphine, a combination of naloxone and buprenorphine, Narcan®, Suboxone®, Subutex®, and the like. The application 130 can indicate whether the overdose victim is conscious or unconscious.
The notification can include protocol for a first responder to render aid to the user. The application 130 can provide the user data to the medical personnel to aid them in administrating the correct dose of medication that reduces or reverses the effects of an overdose, such as naloxone and the like to the user. For example, if the overdose victim is also a heroin or marijuana user, the overdose victim may need a larger dosage of naloxone to reverse the effects of the opioid overdose than an overdose victim that does not also use heroin or marijuana. Further, the naloxone dosage may also need to be adjusted for the weight and age of the overdose victim. For example, a greater dosage on naloxone may be needed to reverse the depressed respiration effects of opioid overdose for an adult than is needed for a small child.
The application can provide trend data to medical personnel or to designated caregivers on a continual basis or may provide the trend data with the overdose notification. The dosage of medication to reduce or reverse the effects of the overdose, such as naloxone and the like, can be adjusted based at least in part on the trend data.
The application 130 can notify the user and request an acknowledgement for the user. For example, the application 130 can provide a visual notification on the display 122, and then cause the mobile computing device 120 to provide an audible notification, such as an audible alarm which can escalate to an increasing louder piercing sound in an attempt to wake up the user. The audible notification can include the name of the user. The application 130 can interact with a home system, such as Alexa®, Amazon Echo®, and the like, to create the alarm. The application 130 can cause the mobile computing device 120 or the home system, for example, to contact a live person who can provide immediate care instructions to the first responder.
The application 130 can provide the notifications to others in the user's community that have downloaded the application 130 on their mobile computing device. The application 130 can cause the mobile computing device 120 to send, for example, but not limited to text messages, emails, and phone calls to selected contacts in the user's mobile device 120, who may or may not have downloaded the application 130 to their mobile computing device 120. The mobile computing device 120 can automatically dial 911 or other emergency response numbers. The application 130 can transmit the location of the user to one or more selected ambulances and paramedics.
Notify a Friend
At block 405, the mobile physiological parameter monitoring system 100 collects raw data 104 from the sensor 102. At block 410, signal processing device 110 processes the raw data and provides the mobile computing device 120 with physiological parameters 118.
At block 415, the mobile computing device 120 receives the physiological parameters 118 from the physiological parameter monitoring device 110.
At block 420, the application 130 displays on the display 122 of the mobile computing device 120 the physiological parameters 118. The mobile computing device 120 can display numerical indications, graphs, pie charts, dials, and the like. The displays can include acceptable and unacceptable ranges for the physiological parameters 118. The display can be color coded. For example, acceptable ranges can be colored green and unacceptable ranges can be colored red. The application 130 can display on the mobile computing device 120 the physiological parameters 118 as the physiological parameters 118 are received (in real time) or at approximately the same time (near real time) as the physiological parameters 118 are received.
At block 425, the application 130 can monitor the physiological parameters 118 for indications of an opioid overdose. The monitored physiological parameters 118 can include the physiological parameters that are most likely affected by an overdose condition. The physiological parameters 118 can be one or more of the oxygen saturation, heart rate, respiration rate, pleth variability, perfusion index, and the like of the user.
The application 130 can determine whether the physiological parameters 118 indicate that the user needs on-site care. A blood oxygen saturation level below a threshold can indicate an opioid overdose condition. For example, the application 130 can monitor the oxygen saturation of the user and trigger an alarm when the oxygen saturation falls below a threshold. The application 130 can compare the user's current oxygen saturation level with a threshold that can indicate a minimum acceptable blood oxygen saturation level. An oxygen saturation level below the minimum acceptable blood oxygen saturation level can be an indication of an overdose event. For example, an oxygen saturation level below approximately 88 can indicate respiratory distress.
The application 130 can compare each of the monitored physiological parameters 118 with a threshold that indicates a minimum or maximum acceptable level for the physiological parameter 118. For example, the application 130 can compare the user's heart rate in beats per minute with the acceptable range of approximately 50 beats per minute to approximately 195 beats per minute. The application 130 can compare the user's respiration rate in breaths per minute with the acceptable range of approximately 6 breaths per minute to approximately 30 breaths per minute. The application 130 can compare the user's pleth the acceptable range of approximately 5 to approximately 40 and the user's perfusion index to a minimum acceptable perfusion index of approximately 0.3.
One or more physiological parameters 118 can be weighted and when the combination of weighted parameters falls below a threshold, the application 130 can trigger the notification of an opioid overdose event. One or more physiological parameters 118 can be weighted based on trends in the user's physiological parameters during opioid use and when the combination of weighted parameters falls below a threshold, the application 130 can trigger the notification of an opioid overdose event.
When the measured physiological parameters 118 are within acceptable ranges, the process 400 can return to block 415 and the mobile computing device 120 can continue to receive the physiological parameters 118 from the sensor 102 via the physiological parameter monitoring device 110. The application 130 can compare one, more than one, or all of the measured physiological parameters 118 to determine an overdose event.
When an overdose is indicated as imminent or occurring, the process 400 moves to block 430. For example, when the user's blood oxygen saturation level is at or below the threshold, the application 130 triggers an alarm at block 430. When at least one of the monitored parameters 118 is below an acceptable threshold, the process 400 can trigger an alarm. The alarm can be an audible alarm that increases in loudness, frequency, or pitch. The alarm can be the user's name, a vibration, or a combination of audible sound, vibration, and name.
The mobile computing device 120 can vibrate, audibly alarm, display a warning, visibly flash, and the like to notify the user or someone at the same physical location as the mobile computing device 120 to the overdose event. The alarm can be an audible alarm that increases in loudness, frequency, or pitch. The alarm can be the user's name, a vibration, or a combination of audible sound, vibration, and name.
The mobile computing device 120 can display the location of and/or direction to naloxone or other medication to reverse or reduce the effects of an overdose closest to the user. The mobile computing device 120 can display the phone number of the person associated with the closest medication to reverse or reduce the effects of an overdose, such as naloxone. The mobile computing device 120 can display resuscitation instructions to the first responder. The mobile computing device 120 can request an acknowledgement from the first responder. The mobile computing device 120 can display the resuscitation instructions to the first responder, call medical personnel, and facilitate questions and answers between the first responder and the medical personnel.
If the user is alone, this may not be enough to avoid a life-threatening overdose condition. At block 435, the application 130 can send a notification to the user's network, such as the person(s), emergency personnel, friends, family, caregivers, doctors, hospitals selected to be notified. The notification can be sent in conjunction with the network connectivity 128 of the user's mobile computing device 120. The notification informs the selected person(s) of the user's opioid overdose. For example, the selected person(s) can receive a notification on their mobile computing device. The selected person(s) can be a friend, a group of friends, first responders, medical personnel, and the like. The mobile computing device 120 can automatically dial 911 or other emergency response numbers.
The notification can be sent to a crowd sourced community of opioid users that look out for one another, such as a community of individuals and/or organizations associated with one or more opioid users. The community functions to provide help to opioid users and can includes not only other opioid users, but friends, family, sponsors, first responders, medics, clinicians, and anyone with access to medication to reverse or reduce the effects of an overdose, such as naloxone.
The notification can be one or more of text message, an automatically dialed phone call, an email, or the like. The notification can include one or more of a graphical representation, a numerical value or the like of the user's unacceptable or out-of-acceptable-range physiological parameter 118, the time of the overdose, the location of the user, directions to the location, and the phone number of the user's mobile computing device 120. The notification can also provide the location of and/or direction to medication to reverse or reduce the effects of an overdose, such as naloxone, closest to the user, as well as the phone number of the person associated with the closest medication to reverse or reduce the effects of an overdose, such as naloxone.
Selecting HISTORY can display the past physiological parameters stored in storage 124 as one or more of graphs, charts, bar graphs, and the like. The application 130 can use the HISTORY to develop trends for the specific opioid user to more accurately determine when an opioid overdose event is imminent.
Heart rate is the speed of the heartbeat measured by the number of contractions of the heart per minute (bpm). The heart rate can vary according to the body's physical needs, including the need to absorb oxygen and excrete carbon dioxide. Selecting HEART RATE RECOVERY can display the recovery heart rate of the user after a near opioid overdose or overdose event.
Selecting NOTIFY A FRIEND allows the user or a caregiver to select a contact from the mobile computing device 120 to be notified in the event that the user's physiological parameters 118 indicate that the user is experiencing or will soon experience an overdose event.
The home screen 530 further includes a setup section that includes DEVICE, SOUND, DATA, MEASUREMENT SETTINGS, APP INTEGRATION, ABOUT, AND SUPPORT. The user can receive information, such as device data, for example, or select setting, such as what measurements are displayed, change alarm volume, and the like.
Assistance for Responders and Caregivers
It is critical to administer an opioid receptor antagonist, such as Naloxone, to victims of opioid overdoses as soon as possible. Often it can be a matter of life or death for the overdose victim. As described herein, self-administrating delivery devices can administer the opioid receptor antagonist without user or responder action. Opioid overdose victims without a self-administrating delivery device rely on the responders, friends, or caregivers that are first on the scene to administer the opioid receptor antagonist. Assistance that can be provided to the first responders can be useful and the assistance can take many forms. The assistance can be visual or auditory indicators and/or instructions. The user can wear a band, such as a wrist band, for example, that changes color to indicate an opioid overdose event. A display, such as a display on a mobile device, can change color, or flash to draw attention when an opioid overdose event is detected. The mobile or other device can transmit a notification or transmit the flashing display to other devices within range to notify others of the opioid overdose event. The display can display instructions that explain how to administer the opioid receptor antagonist, such as Naloxone. The display can display instructions to wake the overdose victim using smelling salts, shaking, escalation of painful stimulation, loud noises, or any combination of these. The responder can be instructed to incrementally increase aggressive actions to wake the overdose victim. An example of incrementally increasing aggressive action can be loud sound, followed by a small amount of painful stimulation, followed by administration of a small amount of Naloxone or other opioid receptor antagonist, followed by an increased amount of painful stimulation. The first responder can be instructed to induce pain using acupuncture. The mobile or other device can speak the instructions to get the attention of others that are nearby. The mobile or other device can speak “Please inject Naloxone” to indicate urgency. The mobile or other device can beep to attract attention. The mobile or other device can buzz and/or provide voice directions to help in directionally finding the overdose victim.
The mobile or other device can provide codes to emergency personnel within proximity. The mobile or other device can send a signal to emergency personnel or police indicating that the Naloxone needs to be delivered as soon as possible.
The first responder can also administer medication to induce vomiting once the overdose victim is awake and upright. The user may regurgitate any opioid substances, such as pills, for example, that are still in the user's stomach.
Network Environment
The network 704 may be any wired network, wireless network, or combination thereof. In addition, the network 704 may be a personal area network, local area network, wide area network, over-the-air broadcast network (e.g., for radio or television), cable network, satellite network, cellular telephone network, or combination thereof. For example, the network 704 may be a publicly accessible network of linked networks such as the Internet. Protocols and components for communicating via the Internet or any of the other aforementioned types of communication networks are well known to those skilled in the art and, thus, are not described in more detail herein.
For example, the opioid user systems 706A . . . 706N and the cloud environment 702 may each be implemented on one or more wired and/or wireless private networks, and the network 704 may be a public network (e.g., the Internet) via which the opioid user systems 706A . . . 706N and the cloud environment 702 communicate with each other. The cloud environment 702 may be a cloud-based platform configured to communicate with multiple opioid user systems 706A . . . 706N. The cloud environment 702 may include a collection of services, which are delivered via the network 704 as web services. The components of the cloud environment 702 are described in greater detail below with reference to
The remote application manager 710 may oversee the monitoring and notifications of associated with the plurality of opioid user systems 706A . . . 706N. The remote application manager 710 is remote in the sense that it is located in a centralized environment as opposed to each opioid user's local environment. The remote application manager 710 may oversee the registration manager 712, the map server manager 714, the distress notification manager 716, and the non-distress notification manager 718. The remote application manager 710 may perform one or more of the steps of
The registration manager 712 may manage the information associated with each opioid user registrant and the contact information supplied by each opioid user registrant during registration for the opioid overdose monitoring system. The contact information may include the names, phone number, email addresses, etc. of individuals and/or organizations to contact on behalf of the opioid user when an overdose event is predicted or detected, or for status check information, as well as the name, address, phone number, email address, etc. of the opioid user registrant. Examples of individuals and organizations are illustrated in
The map server manager 714 may locate maps and directions, such as those illustrated in
The distress notification manager may receive an alert from the opioid user's mobile device that an overdose event may soon occur or has occurred. For example, the mobile device 120 or the monitoring device 110 may process the sensor data from the sensors 102 and determine that an overdose event is occurring. The mobile device 120 may communication the occurrence of overdose event with the distress notification manager 716. The distress notification manager 716 may retrieve contact information from the database 720 and provide notification of the overdose event or a soon to occur overdose event to the individuals and organizations indicated by the opioid user during registration so that assistance can be provided to the opioid user.
The non-distress notification manager 714 may receive the status of the opioid user as monitored by the mobile device 120 and/or the monitoring device 110. The non-distress notification manager 718 may receive the status periodically. After determining that the status of the opioid user indicates that the opioid user is not in distress, the non-distress notification manager may access the database 720 to retrieve the contact information for the individual and organizations that are to be notified of the well-being of the opioid user.
The illustrated mobile communication device 722 includes a display 724, similar to display 122, described herein, a network interface 726 that is configured to communication at least with the cloud environment 702 via the network 704, a local application 728, a monitoring application 730, a distress application 732, a non-distress application 734, a query opioid user application 736, and a local alarm application 738. The local application 728, the monitoring application 730, the distress application 732, the non-distress application 734, the query opioid user application 736, and the local alarm application 738 may be software instructions stored in memory within the mobile communication device 722 that are executed by the computing devices within the mobile communication device 722. The applications 728-738 can be downloaded onto the mobile communication device 722 from a third party or from the cloud environment 702. The mobile communication device 722 may include more or fewer components than those illustrated in
The local application 728 may oversee the communication with the remote monitoring manager of the cloud environment and may oversee the monitoring application 730, the distress application 732, the non-distress application 734, the query opioid user application 736, and the local alarm application 738. The local application 728 is local in the sense that it as well as its associated applications 730-738, are located on the mobile communication device 722 associated with the opioid user, devices associated with organizations to assist opioid users, and devices associated with individuals that are associated with the opioid user.
The monitoring application 730 may receive the physiological parameters 118 and process the physiological parameters according to one or more of the steps of
The distress application 732 may be called when the monitoring application 730 determines that the opioid user is experiencing an overdose event or an overdose event is imminent. The distress application 732 may perform one or more steps of
The non-distress application 734 may be called when the monitoring application 730 determines that the opioid user is not experiencing an overdose event or an overdose event is not imminent. The non-distress application 734 may perform one or more steps of
The query opioid user application 736 may be called when the monitoring application 730 determines that care is indicated. The query opioid user application 736 queries the user to determine whether the user is conscious in order to reduce false alarms. The query opioid user application 736 may perform step 235 of
The local alarm application 738 may be called when the monitoring application 730 determines that on-site care of the opioid user is required. The local alarm application 738 may perform step 430 of
At block 802, the cloud environment 702 may determine, based on the status of the user, whether care is indicated. The status information may comprise the physiological parameters 118 from the monitoring application 730. The status may be an indication of whether care is indicated or not indicated. Remote application manager 710 may analyze the physiological parameters 118 to determine whether care is indicated.
If care is indicated at block 804, the process 800 moves to block 806. At block 806, the distress notification manager 716 may retrieve the contact information stored in the database and associated with the user identification.
At block 808, the distress notification manager 716 may notify the individuals and organizations of the contact information of the need for care.
If care is not indicated at block 804, the process 800 moves to block 810. At block 810, the non-distress notification manager 718 may retrieve the contact information stored in the database and associated with the user identification.
At block 812, the non-distress notification manager 718 may notify the individuals and organizations of the contact information of the status of the opioid user. The non-distress notification manager 718 can send an “Everything OK” message.
Communication Between Opioid Overdose Monitoring Application and Transportation/Ride Sharing Services
A mobile device or other computing device executing the opioid monitoring application can communicate with one or more transportation services such as, a ride sharing service, such as Lyft® or Uber®, for example, a taxi service, or any commercial transportation service, when an overdose event is occurring or imminent. This is illustrated in
The transportation service can receive a notification from the mobile device or other computing device that is deploying the opioid overdose monitoring application. The notification can be an alert. The alert may be for an ongoing or an imminent opioid overdose event. The notification may include the address of the opioid user, the address of the nearest facility with medication to reverse or reduce the effects of an overdose, such as naloxone, buprenorphine, combination of buprenorphine and naloxone, and the like, and the address of the nearest caregiver, emergency service, treatment center, and other organizations or individuals that can provide life-saving care to for the opioid user.
The transportation service can transport the opioid user to receive care, transport the opioid user to a location having the medication, transport the medication to the opioid user, to pick up the medication and transport the medication to the opioid user, and the like.
The transportation service or ride sharing service can bill for the transportation that occurs after receiving an alert or notification generated by the opioid overdose monitoring application as a special billing or a charitable billing. The transportation service or ride sharing service can bill for the transportation in the same manner that its transportation services are billed for a typical customer.
The transportation service or ride sharing service can participate in a community outreach program to provide transportation responsive to receiving an alert or notification generated by the opioid monitoring application.
Physiological Monitoring and Medication Administration System Including Activation Circuitry
The applicator 904 can be worn by the user in a manner that facilitates the application of the medication. For example, the applicator 904 can be strapped to the user's wrist, as illustrated in
The activation circuitry 1206 is configured receive an activation signal via the antenna 1214 and activate a delivery mechanism 1208 to dispense medication in the reservoir 1210 through the needle 1212 through the skin, intramuscularly or intravenously. The medication can be naloxone, an opioid receptor antagonist, or the like to reduce the effects of an opioid overdose event. The delivery mechanism 1208 can be a plunger propelled forward by a propellant such as a CO2 cartridge, gas squib, compressed air, and N2 gas cartridge, a pump motor, spring, and the like. The pressure from the delivery mechanism 1208 pushes the medication through the needle and causes the needle 1212 to move forward through the adhesive layer 1202 and into the skin, muscle, vein or the like at the deliver site. The needle 1212 can be a hypodermic needle or any sharp configured to inject substances into the body. The applicator 1200 deposits the medication in the tissue under the administration site.
The applicator 1100 can further comprise an opioid overdose detection sensor 1406, which can be considered a local opioid overdose detection sensor because it is local to the user. The local opioid overdose detection sensor 1406 can receive sensor data from the opioid user. Local opioid overdose detection sensor 1406 sends the sensor data to the processing circuitry 1402. The processing circuitry 1402 receives the sensor data from the local opioid overdose detection sensor 1406, processes the sensor data, and determines whether an opioid overdose event is occurring or will soon be occurring. The local opioid overdose detection sensor 1406 can send the sensor data to the transceiver 1404. The transceiver 1404 sends the sensor data via the one or more antenna 1414 to at least one of the mobile device 120, the server, and the hub for processing. Once the data is processed, the transceiver 1404 can receive via one or more antenna 1414 a signal indicating that the opioid overdose event is occurring or soon will be occurring. The transceiver 1404 sends the processing circuitry 1402 an indication that the opioid overdose event is occurring or soon will be occurring.
The applicator 1100, 1200 may not include an opioid overdose detection sensor 1408, such that the opioid overdose detection sensor 1408 can be considered remote from the applicator 1100, 1200. The remote opioid detection sensor 1408 can send the sensor data to at least one of the mobile device 120, the server, and the hub and when the processed sensor data indicates that an opioid overdose event is occurring, the transceiver 1404 receives via one or more antenna 1414 a signal indicating that an opioid overdose event is occurring or soon will be occurring. The transceiver 1404 sends the processing circuitry 1402 an indication that the opioid overdose event is occurring or soon will be occurring. The remote opioid detection sensor 1408 can send sensor data wirelessly or through a wired connection to the processing circuitry 1402.
The processing circuitry 1402 can determine that the opioid overdose event is occurring or will soon occur by processing the sensor data from the local opioid overdose detector sensor 1406 or can receive an indication from the transceiver 1404 that the opioid overdose event is occurring or will soon occur. The processor 1402 can generate one or more activate signals ACTIVATE(1) to ACTIVATE(N) to the delivery systems DELIVERY(1) to DELIVERY(N), respectively, to dispense one or up to N doses of the medication. For example, if the physiology of the user is such that a single dose of medication is insufficient, the processing circuitry 1402 may be programmed to deliver multiple doses at approximately the same time.
The processing circuitry 1402 can generate more than one activate signal at approximately the same time to deliver more than one dose of the medication to the user at approximately the same time. The processing circuit 1402 can generate successive activate signals in response to successive indications of an overdose event. For example, if the application of a first dose of medication does not reverse the effects of an opioid overdose, the processing circuitry 1402 can generate a second activation signal to provide a second dose of medication to the user. The activation circuitry 1400 can count the number of doses dispensed and provides an alert when the applicators 1100, 1200 are empty.
Referring to
Referring to
Patch with Pressurized Reservoir
The reservoir 1710 can include an opioid receptor antagonist, such as Naloxone which is dispensed via the needle 1712 into the user. The needle 1712 can be a microneedle. Sensor 1716 can be internal to the patch 1700 and monitors the user's physiological parameters. Instead of the patch 1700 including an internal sensor 1716, an external sensor 1717 can monitor the user's physiological parameters and can wirelessly communicate with the patch 1700 via the antennas. The external sensor 1717 can be wired to the patch 1700 and provide the sensor data via wires. External sensor 1717 can be a finger sensor that wraps around or over a finger or a toe a Sensor 1716 or sensor 1718 can include pulse oximeters, respiratory monitors, and other sensor devices disclosed herein that monitor the user's physiological parameters. The processor 1714 can process the sensor data to detect an overdose event. The patch 1700 can transmit the sensor data to an external processing device, such as a mobile device or a hub device for detection of an opioid overdose event.
The needle 1712 can be spring-loaded (e.g., in a switch-blade like manner). Fabric layer 1720 can hold the spring-loaded needle 1712 in a compressed state without the spring-loaded needle puncturing the fabric layer 1720. When an opioid overdose event is detected, the battery 1718 can release a charge that passes through at least a portion of the fabric layer 1720. The fabric layer 1720 receives the electrical charge from the battery 1718, which can cause the fabric layer 1720 to burn or shrink and the spring-loaded needle to be no longer restrained. The needle 1712 releases and can inject the user with the opioid receptor antagonist, such as Naloxone, stored in the reservoir. The reservoir 1710 can be pressurized to assist in the injection of the opioid receptor antagonist when the needle is released. An external pump can pressurize the reservoir 1710. The patch 1700 can have no mechanical triggers. The battery 1718 can be sized to provide operating power for approximately one week. The battery 1718 can be sized to provide operating power for more than one week, more than two weeks, more than one month, or greater periods of time.
Hub Based Opioid Monitoring System
Delivery device 1804 can be a self-administrating device, such as devices 940, 950, 1100, 1200, 1700. The delivery device can be a device that is user or responder activated. The sensor 1802 can be internal to the delivery device 1804. The sensor 1802 can be external to the delivery device 1804.
The hub device 1806 can be configured to collect data and transmit the data to a cloud server for evaluation. The hub device 1806 can comprise communications circuitry and protocols 1810 to communication with one or more of the delivery device 1804, the sensor 1802, network 1812, mobile communication device 1818, such as a smart phone and the like, and other devices with monitoring capabilities 1816. Communications can be Bluetooth or Wi-Fi, for example. The hub device 1806 can further comprise memory for data storage 1807, memory for application software 1808, and a processor 1809. The application software can include a reminder to put on the patch before sleeping. The hub device 1806 is powered by AC household current and includes battery backup circuitry 1818 for operation when the power is out. The hub device 1806 can be powered through a USB port, using a charger connected to an AC outlet or connected to an automobiles USB charging port. The hub device 1806 can annunciate a battery-low condition.
The hub device 1806 can be a Radius-7® by Masimo, Irvine, Calif. The hub 1806 can comprise at least the memory for data storage 1807 and the battery backup circuitry 1818 can physically interface and communicate with the Radius-7®. The hub device 1806 can interface with the phone cradle of the Radius-7®.
The sensor 1802 can monitor the user's physiological parameters and transmit the raw sensor data to the delivery device 1804, via wired or wireless communication. Optionally, the sensor 1802 can transmit the raw sensor data to the hub device 1806, via wired or wireless communication. The delivery device 1804 can process the raw sensor data to determine when an opioid overdose event occurs. The hub device 1806 can process the raw sensor data to determine when an opioid overdose event occur. The hub device 1806 can transmit the raw sensor data to a cloud server for processing to determine when an opioid overdose event occurs. When an opioid overdose event is imminent or occurring, the cloud server can transmit to the delivery device 1804 via the hub device 1806 instructions to activate and deliver the opioid receptor antagonist, such as Naloxone. The cloud server can further transmit messages to contacts 1814, such as friends, family emergency personnel, caregivers, police, ambulance services, other addicts, hospitals and the like. The hub device 1806 can send the delivery device 1804 instructions to activate.
It is important to avoid false-positive indications of an overdose event. Users may not wear the self-administrating delivery device 1804 if the user experiences delivery of the opioid receptor antagonist when an overdose event is not occurring or imminently going to occur. To avoid false-positive indications, the wearable delivery device 1804 can induce pain before administrating the opioid receptor antagonist when an overdose event is detected to inform the user that the antagonist will be administered. The wearable delivery device 1804 can provide electric shocks to the user to induce pain. The induced pain can escalate until a threshold is reached. The user can employ a manual override to indicate that the user is conscious and not in need of the opioid receptor antagonist. The override can be a button, switch, or other user input on the delivery device 1804, the mobile communication device 722 and/or the hub device 1806. The delivery device 1804, the mobile communication device 722 and/or the hub device 1806 can wait for the user input for a period of time before triggering the release of the opioid receptor antagonist to avoid false-positive indications. The period of time can be less than 1 minute, less than 5 minutes, less than 10 minutes, between 1 minute and 5 minutes, between 1 minute and 10 minutes, and the like.
The memory for data storage 1807 can store the raw sensor data. The memory for data storage can act as a “black box” to record data from a plurality of sources. It is critical to administer the opioid receptor antagonist to a user as soon as an opioid overdose event is detected. The opioid overdose event can be cessation of respiration or an indication that respiration will soon cease. The administration can be by a responder, such as a friend or emergency personnel, by a self-administrating device worn by the user, or by the user. To avoid missing any signs that lead to an opioid overdose event, the hub device 1806 can receive data from any devices with a monitoring capability. For example, many homes have household cameras which provide a video feed. Cell phones can provide text messages and also include microphones to record voice. The cell phone or smart phone can be configured to listen to breathing and transmit the breathing data. Intelligent personal assistants, such as Amazon's Alexa® controlled Echo speaker, Google's Google Assistant®, Apple's Siri®, and the like, for example, also include microphones and have the ability to interface with the Internet. Many household appliances, such as refrigerators, washing machines, coffee makers, and the like, include Internet of Things technology and are also able to interface with the Internet. Medical monitoring devices that are being used by the opioid user for medical conditions, such as ECG's may also provide additional data. Data from one or more of these devices can be stored in the memory 1807 and used by the hub device 1806 or sent to the cloud server and used by the cloud server to detect an opioid overdose event. The hub device 1806 can determine what monitoring and Internet-connected devices are available and connect wirelessly to the available monitoring and Internet connected devices to receive data.
The hub device 1806 can interface with an internet filter, such as a Circle® internet filter that connects to a home network to monitor content. The hub device 1806 can determine which network data is directed to the user's well-being and store the well-being data.
The data can comprise text messages, voice recordings, video, and the like. Because of privacy concerns, the hub device 1806 can determine which small portions of data are helpful to determining the user's physical condition and store only those portion of data.
Because devices can fail to connect to the Internet, it is important to have redundant systems to report the sensor data for overdose detection. In the event that the hub device 1806 fails to connect to the Internet 1812, the mobile device or other internet-connected devices found in the home can provide an internet connection. For example, the hub device 1806 can transmit the sensor data to the mobile device 1818 and the mobile device 1818 can transmit the sensor data to the cloud server for processing. The sensor 1802 or delivery device 1804 can communicate with the mobile device 1818 when the hub device to Internet connection fails. Intelligent personal assistants and IoT devices can also provide redundant (backup) internet communication. The hub device 1806 can annunciate when its internet connection fails.
The mobile device 1818 can monitor respiration rate, SPO2, or ECG in parallel with the sensor 1802 and hub device 1806 monitoring of the user's physiological parameters to increase the likelihood that an imminent overdose will be detected. The sensor 1802 can monitor the concentration of an opioid in the user's bloodstream. The measured concentration can be a factor in determining an opioid overdose event to reduce instances of false positives.
A home security monitoring system can include the hub device 1806 and a home security company can monitor the user's health via the hub device 1806 and sensor 1802.
The opioid overdose monitoring application can be integrated into intelligent personal assistants, such as Amazon's Alexa®, for example.
The delivery device 1804 can include medication to induce vomiting. The opioid user can ingest the vomit-inducing medication, if desired, to regurgitate any opioid substance remaining in the user's stomach. The delivery device 1804 can include reservoirs containing the vomit-inducing medication and a position-sensing sensor. The vomit-inducing medication can be automatically dispensed after receiving sensor input indicating that the user is in an upright position.
The position-sensing sensor can monitor the user's movements to determine that the user is upright. The delivery device 1804 can include one or more sensors configured to obtain position, orientation, and motion information from the user. The one or more sensors can include an accelerometer, a gyroscope, and a magnetometer, which are configured to determine the user's position and orientation in three-dimensional space. The delivery device 1804 or the hub device 1806 can be configured to process the received information to determine the position of the user.
At block 1854, the hub device 1806 can store the raw sensor data. At block 1856, the hub device 1806 can collect and store data associated with the user's well-being from other devices local to the user. For example, the hub device can receive data from one or more home cameras, data from microphones and cameras of intelligent home assistants, such as Alexa®, for example, internet data from a home internet filter, and the like.
At block 1858, the hub device 1806 can transmit via the network 1812, the stored data to a cloud server for processing. The cloud server can process the data to determine whether an opioid overdose event is occurring or will be imminent. At block 1860, the hub device 1806 can receive from the cloud server an indication that an opioid overdose event is occurring or imminent. The hub device 1806 can transmit the indication to the delivery device 1804.
At block 1862, the delivery device 1804 can provide the user with escalating actions to prompt the user to activate a manual override to indicate that the opioid overdose event is not occurring. For example, the delivery device can provide increasing electric shocks to the user, up to a threshold.
At block 1864, the delivery device 1804 can determine whether an override from the user has been received. When an override is indicated, such as from a user activated button or switch on the delivery device 1804, the process 1850 returns to block 1852 to continue collecting physiological parameters. When an override is not indicated, the process 1850 moves to block 1866. At block 1866, the delivery device 1804 administers the medication, such as Naloxone or other opioid receptor antagonist and returns to block 1852 to continue monitoring the physiological parameters.
FIG. 18A1 is an example screenshot illustrating a welcome message to a new user of the opioid overdose monitoring application. The illustrated screenshot of FIG. 18A1 displays an illustration of a hand wearing an example sensor and signal processing device 1802. The user can create an account for the overdose monitoring application. Once account registration is successful, the example application 1808 can instruct the user to set up the communications between the mobile device 1818, the sensor and signal processing device 1802, the medical monitoring hub device 1806, and the home Wi-Fi network.
FIG. 18A2 is an example screenshot illustrating instructions to the user to power the medical monitoring hub device 1806 to wireless connect to the mobile device 1818. For example, the medical monitoring hub device 1806 can be Bluetooth enabled. FIG. 18A3 is an example screenshot illustrating that the medical monitoring hub device 1806 is successfully connected.
FIGS. 18A4-18A6 are example screenshots illustrating instructions to power the sensor and signal processing device 1802 in order to wirelessly connect to the medical monitoring hub device 1806. The illustrated screenshot of FIG. 18A4 displays an illustration of the signal processing portion of the sensor and signal processing device 1802 in an open state to receive an integrated circuit (“chip”). The illustrated screenshot of FIG. 18A5 displays an illustration of the signal processing portion of the sensor and signal processing device 1802 in a closed state. The illustrated screenshot of FIG. 18A6 displays an illustration of the sensor portion of the sensor and signal processing device 1802 in a powered state.
FIG. 18A7-18A8 is are example screenshots illustrating instructions to pair the powered sensor and signal processing device 1802 with the medical monitoring hub device 1806. For example, the sensor and signal processing device 1802 can be Bluetooth enabled.
The user can allow the software application to access Wi-Fi settings for a router on a local network, such as a home network. The user can access the Wi-Fi hub setup and choose a network from a list of available networks local to the user. The illustrated screenshot of FIG. 18A9 is an example screenshot displaying an indication that the medical monitoring hub device 1806 is connecting to the local network.
FIG. 18A10 is an example screenshot asking the user to allow the software application to access location information. When the software application has access to the user's location information such as the location information found on the user's mobile device 1818, the software application can provide the user's location to emergency personnel, caregivers, friends, and family, etc. when they are notified of an overdose event.
FIG. 18A11 is an example screenshot displaying an indication that the medical monitoring hub device 1806 is connecting to the cloud server 1812 via the local network. After the setup is complete, the medical monitoring hub device 1806 can communicate with the sensor and signal processing device 1802, the mobile device 1818 running the software application, and the could server 1812.
FIG. 18A12 is an example screenshot displaying a prompt to the user to add contact information for the respondents to be notified of an opioid overdose event that is occurring or will soon occur. the user can select, for example, from the list of contacts found in the mobile device 1818.
FIG. 18A13 is an example screenshot illustrating a selected respondent to be notified in the event of an opioid overdose event, where the opioid overdose event can be an overdose that is presently occurring or, based on the user's physiological parameters sensed by the sensor and signal processing device 1802, will soon occur. The selected respondent can also be notified of situations that may cause the opioid monitoring system to fail if not corrected, such as when the user is not wearing the sensor or the sensor battery is low. The illustrated screenshot of FIG. 18A13 displays the selected respondent's name and phone number and provides a selection of alerts that the user can choose the respondent to receive. The example selections include a parameter alert, a sensor off alert, and a battery low alert. The parameter alert can be sent when the monitored physiological parameter falls outside a range of acceptable values. The sensor off alert can be sent when the user is not wearing the sensor and signal processing device 1802. The batter low alert can be sent when the battery voltage in the sensor and signal processing device 1802 fall below a threshold value.
FIG. 18A19 is an example screenshot illustrating a selection of parameter notifications to be sent to the selected respondent. In the illustrated screenshot of
FIGS. 18A14-18A15 are example screenshots illustrating the real time monitoring of the user's physiological parameters. The illustrated screenshots of FIGS. 18A14-18A15 display representation of dials indicating the monitored oxygen saturation, heart rate in beats per minute, and perfusion index. The illustrated screenshot of FIG. 18A14 indicates that the monitored oxygen saturation (96), heart rate 102), and perfusion index (8.5) are acceptable values. The illustrated screenshot of FIG. 18A15 indicates that the monitored oxygen saturation (86) is no longer within an acceptable range.
FIG. 18A16 is an example screenshot displaying a warning message to the user that the sensor is disconnected.
FIG. 18A17 is an example screenshot illustrating historical averages of the user's monitored physiological parameters. The illustrated screenshot of FIG. 18A17 displays the average oxygen saturation, heart rate, and perfusion index for the period of time the sensor and signal processing device 1802 collected data for two dates, March 11, and March 12.
FIG. 18A18 is an example screenshot illustrating session data for oxygen saturation, heart rate, and perfusion index on March 7. The displayed information in the illustrated example includes the minimum, maximum and average of the monitored physiological parameter.
FIG. 18A20 is an example screenshot illustrating sound options available for the software application. In the illustrated screenshot of FIG. 18A20, the software application can cause the mobile device 1818 to play a sound, such as a beep, that coincides with the user's pulse, play a sound, such as a beep, when a measurement value breaches its threshold range, and play a beep sound even when the software application is running in the background.
FIG. 18A21 is an example screenshot illustrating customizable alarm values. Some users may have a higher tolerance for opioids and an opioid event may not be occurring when the user's physiological parameters fall within a range that typically signals an opioid overdose event. It is desirable to avoid false alarms that may desensitize respondents to notifications. In the illustrated screenshot of FIG. 18A21, the ranges for a red, orange, and yellow alarms for oxygen saturation can be customized for the user by, for example, sliding the indicators along the green-yellow-orange-red bar until the desired values are displayed. Selecting beats/minute and pleth variability permits the user to customize the alarm ranges for heart rate and perfusion index, respectively.
FIG. 18A22 is an example screenshot illustrating that the user's physiological parameter data can be shared with other health monitoring applications, such as Apple Health.
FIG. 18A23 is an example screenshot illustrating a reminder to put on the sensor and signal processing device 1802 before going to bed. The software application may provide other reminders, such as time to replace the sensor battery, turn on notifications, and the like.
FIGS. 18A24-18A25 are example screenshots illustrating a request for user input when the user's physiological parameters indicate an opioid overdose event is occurring or will soon occur. To avoid sending false alarms, the software application requests user input to confirm that the user is not unconscious or otherwise does not want alarm notifications to be send to respondents. In the illustrated screenshot of FIG. 18A24, the user is asked to swipe the screen to confirm safety. In the illustrated screenshot of FIG. 18A25, the user is asked to enter an illustrated pattern on the screen to confirm safety. Different user inputs can be used to confirm different cognitive abilities of the user. For example, it is more difficult to enter the illustrated pattern of FIG. 18A25 than to swipe the bottom of the screen in FIG. 18A24.
Opioid Monitoring Kits
Other Delivery Methods/Mechanisms
As discussed herein, opioid receptor antagonists can be delivered by intravenous injection, intramuscular injection, and intranasal application, where a liquid form of the medication is sprayed into the user's nostrils. Administration of the medication can also occur via an endotracheal tube, sublingually, where a gel or tablet of the medication is applied under the tongue, and transdermally, where the medication can be a gel applied directly to the skin or within a transdermal patch applied to the skin.
Other methods of administrating the opioid receptor antagonist can be via rectal capsule or suppository. The capsule can also monitor respiration rate and/or pulse rate and rupture the capsule when an opioid overdose event is imminent or occurring. A Bluetooth© signal can activate the capsule.
The opioid receptor antagonist can be included in an inhaler, by first injecting the user with an antiseptic and then with the opioid receptor antagonist, or in administered in an ear or other body orifice. The opioid receptor antagonist can be delivered through a cannula for a ventilator or breathing machine, for example.
The opioid receptor antagonist can be stored in a dental retainer that is crushed to release the stored drug.
An implantable delivery device can deliver the opioid receptor antagonist for chronic opioid users. The device can be implanted in a similar location as a pacemaker. The device can monitor one or more of respiration rate, pulse rate, ECG and SPO2 and release a dose of opioid receptor antagonist when an opioid overdose event is detected. The implantable device can comprise multiple doses and/or can be refillable by injecting the opioid receptor antagonist into the implantable delivery device. Such as delivery device can be implanted for one or more months. Another example of an implantable delivery device comprises a capsule containing the opioid receptor antagonist and an external device, such as a strap over the capsule that transmits a resonant frequency. The resonant frequency causes the capsule to rupture and the released opioid receptor antagonist is absorbed by the body.
The opioid receptor antagonist is contained in a pill that is activated when needed. The opioid receptor antagonist can be encased in a gel pack that is ingested or worn on the skin. An ultrasonic device, worn as a wrist strap, for example, can rupture the gel pack, adhered to the skin, for example, when an opioid overdose event is detected. The body can absorb the opioid receptor antagonist from the ruptured gel pack.
Terminology
The embodiments disclosed herein are presented by way of examples only and not to limit the scope of the claims that follow. One of ordinary skill in the art will appreciate from the disclosure herein that many variations and modifications can be realized without departing from the scope of the present disclosure.
The term “and/or” herein has its broadest least limiting meaning which is the disclosure includes A alone, B alone, both A and B together, or A or B alternatively, but does not require both A and B or require one of A or one of B. As used herein, the phrase “at least one of” A, B, “and” C should be construed to mean a logical A or B or C, using a non-exclusive logical or.
The description herein is merely illustrative in nature and is in no way intended to limit the disclosure, its application, or uses. For purposes of clarity, the same reference numbers will be used in the drawings to identify similar elements. It should be understood that steps within a method may be executed in different order without altering the principles of the present disclosure.
As used herein, the term module may refer to, be part of, or include an Application Specific Integrated Circuit (ASIC); an electronic circuit; a combinational logic circuit; a field programmable gate array (FPGA); a processor (shared, dedicated, or group) that executes code; other suitable components that provide the described functionality; or a combination of some or all of the above, such as in a system-on-chip. The term module may include memory (shared, dedicated, or group) that stores code executed by the processor.
The term code, as used above, may include software, firmware, and/or microcode, and may refer to programs, routines, functions, classes, and/or objects. The term shared, as used above, means that some or all code from multiple modules may be executed using a single (shared) processor. In addition, some or all code from multiple modules may be stored by a single (shared) memory. The term group, as used above, means that some or all code from a single module may be executed using a group of processors. In addition, some or all code from a single module may be stored using a group of memories.
The apparatuses and methods described herein may be implemented by one or more computer programs executed by one or more processors. The computer programs include processor-executable instructions that are stored on a non-transitory tangible computer readable medium. The computer programs may also include stored data. Non-limiting examples of the non-transitory tangible computer readable medium are nonvolatile memory, magnetic storage, and optical storage. Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. Additionally, other combinations, omissions, substitutions and modifications will be apparent to the skilled artisan in view of the disclosure herein. Accordingly, the present invention is not intended to be limited by the reaction of the preferred embodiments, but is to be defined by reference to claims.
Conditional language used herein, such as, among others, “can,” “might,” “may,” “e.g.,” and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements and/or states. Thus, such conditional language is not generally intended to imply that features, elements and/or states are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without author input or prompting, whether these features, elements and/or states are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list. Further, the term “each,” as used herein, in addition to having its ordinary meaning, can mean any subset of a set of elements to which the term “each” is applied.
While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it will be understood that various omissions, substitutions, and changes in the form and details of the devices or algorithms illustrated can be made without departing from the spirit of the disclosure. As will be recognized, certain embodiments of the inventions described herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others.
Additionally, all publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
This application is a continuation of U.S. application Ser. No. 16/432,739 titled “Opioid Overdose Monitoring,” filed on Jun. 5, 2019, which claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. Provisional Application Nos. 62/681,309 filed on Jun. 6, 2018 and titled “Opioid Overdose Monitoring,” 62/716,469 filed on Aug. 9, 2018 and titled “Opioid Overdose Monitoring,” 62/733,314 filed on Sep. 19, 2018 and titled “Opioid Overdose Monitoring,” 62/745,031 filed on Oct. 12, 2018 and titled “Opioid Overdose Monitoring,” 62/792,998 filed on Jan. 16, 2019 and titled “Opioid Overdose Monitoring,” 62/810,156 filed on Feb. 25, 2019 and titled “Opioid Overdose Monitoring,” 62/836,855 filed on Apr. 22, 2019 and titled “Opioid Overdose Monitoring,” and 62/745,243 filed on Oct. 12, 2018 and titled “Medical Systems and Methods,” the entireties of which are incorporated herein by reference. This application is related to U.S. application Ser. No. 16/432,756 filed on Jun. 5, 2019 and titled “Opioid Overdose Monitoring,” U.S. application Ser. No. 16/432,703 filed on Jun. 5, 2019 and titled “Opioid Overdose Monitoring,” U.S. application Ser. No. 16/928,531 filed on Jul. 14, 2020 and titled “Locating a Locally Stored Medication,” and U.S. application Ser. No. 17/116,155 filed on Dec. 9, 2020 and titled “Kit of Opioid Overdose Monitoring,” the entireties of which are incorporated herein by reference. Any and all applications for which a domestic priority claim is identified in the Application Data Sheet of the present application are hereby incorporated by reference under 37 CFR 1.57.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4960128 | Gordon et al. | Oct 1990 | A |
| 4964408 | Hink et al. | Oct 1990 | A |
| 5041187 | Hink et al. | Aug 1991 | A |
| 5069213 | Hink et al. | Dec 1991 | A |
| 5163438 | Gordon et al. | Nov 1992 | A |
| 5319355 | Russek | Jun 1994 | A |
| 5337744 | Branigan | Aug 1994 | A |
| 5341805 | Stavridi et al. | Aug 1994 | A |
| D353195 | Savage et al. | Dec 1994 | S |
| D353196 | Savage et al. | Dec 1994 | S |
| 5377676 | Vari et al. | Jan 1995 | A |
| D359546 | Savage et al. | Jun 1995 | S |
| 5431170 | Mathews | Jul 1995 | A |
| 5436499 | Namavar et al. | Jul 1995 | A |
| D361840 | Savage et al. | Aug 1995 | S |
| 5441047 | David et al. | Aug 1995 | A |
| D362063 | Savage et al. | Sep 1995 | S |
| 5452717 | Branigan et al. | Sep 1995 | A |
| D363120 | Savage et al. | Oct 1995 | S |
| 5456252 | Vari et al. | Oct 1995 | A |
| 5479934 | Imran | Jan 1996 | A |
| 5482036 | Diab et al. | Jan 1996 | A |
| 5490505 | Diab et al. | Feb 1996 | A |
| 5494043 | O'Sullivan et al. | Feb 1996 | A |
| 5533511 | Kaspari et al. | Jul 1996 | A |
| 5534851 | Russek | Jul 1996 | A |
| 5544649 | David et al. | Aug 1996 | A |
| 5561275 | Savage et al. | Oct 1996 | A |
| 5562002 | Lalin | Oct 1996 | A |
| 5590649 | Caro et al. | Jan 1997 | A |
| 5602924 | Durand et al. | Feb 1997 | A |
| 5632272 | Diab et al. | May 1997 | A |
| 5638816 | Kiani-Azarbayjany et al. | Jun 1997 | A |
| 5638818 | Diab et al. | Jun 1997 | A |
| 5645440 | Tobler et al. | Jul 1997 | A |
| 5671914 | Kalkhoran et al. | Sep 1997 | A |
| 5685299 | Diab et al. | Nov 1997 | A |
| 5726440 | Kalkhoran et al. | Mar 1998 | A |
| D393830 | Tobler et al. | Apr 1998 | S |
| 5743262 | Lepper, Jr. et al. | Apr 1998 | A |
| 5747806 | Khalil et al. | May 1998 | A |
| 5750994 | Schlager | May 1998 | A |
| 5758644 | Diab et al. | Jun 1998 | A |
| 5760910 | Lepper, Jr. et al. | Jun 1998 | A |
| 5769785 | Diab et al. | Jun 1998 | A |
| 5782757 | Diab et al. | Jul 1998 | A |
| 5785659 | Caro et al. | Jul 1998 | A |
| 5791347 | Flaherty et al. | Aug 1998 | A |
| 5810734 | Caro et al. | Sep 1998 | A |
| 5823950 | Diab et al. | Oct 1998 | A |
| 5830131 | Caro et al. | Nov 1998 | A |
| 5833618 | Caro et al. | Nov 1998 | A |
| 5860919 | Kiani-Azarbayjany et al. | Jan 1999 | A |
| 5890929 | Mills et al. | Apr 1999 | A |
| 5904654 | Wohltmann et al. | May 1999 | A |
| 5919134 | Diab | Jul 1999 | A |
| 5934925 | Tobler et al. | Aug 1999 | A |
| 5940182 | Lepper, Jr. et al. | Aug 1999 | A |
| 5987343 | Kinast | Nov 1999 | A |
| 5995855 | Kiani et al. | Nov 1999 | A |
| 5997343 | Mills et al. | Dec 1999 | A |
| 6002952 | Diab et al. | Dec 1999 | A |
| 6010937 | Karam et al. | Jan 2000 | A |
| 6011986 | Diab et al. | Jan 2000 | A |
| 6027452 | Flaherty et al. | Feb 2000 | A |
| 6036642 | Diab et al. | Mar 2000 | A |
| 6040578 | Malin et al. | Mar 2000 | A |
| 6045509 | Caro et al. | Apr 2000 | A |
| 6066204 | Haven | May 2000 | A |
| 6067462 | Diab et al. | May 2000 | A |
| 6081735 | Diab et al. | Jun 2000 | A |
| 6088607 | Diab et al. | Jul 2000 | A |
| 6110522 | Lepper, Jr. et al. | Aug 2000 | A |
| 6115673 | Malin et al. | Sep 2000 | A |
| 6124597 | Shehada et al. | Sep 2000 | A |
| 6128521 | Marro et al. | Oct 2000 | A |
| 6129675 | Jay | Oct 2000 | A |
| 6144868 | Parker | Nov 2000 | A |
| 6151516 | Kiani-Azarbayjany et al. | Nov 2000 | A |
| 6152754 | Gerhardt et al. | Nov 2000 | A |
| 6157850 | Diab et al. | Dec 2000 | A |
| 6163281 | Torch | Dec 2000 | A |
| 6165005 | Mills et al. | Dec 2000 | A |
| 6184521 | Coffin, IV et al. | Feb 2001 | B1 |
| 6206830 | Diab et al. | Mar 2001 | B1 |
| 6229856 | Diab et al. | May 2001 | B1 |
| 6232609 | Snyder et al. | May 2001 | B1 |
| 6236872 | Diab et al. | May 2001 | B1 |
| 6241683 | Macklem et al. | Jun 2001 | B1 |
| 6253097 | Aronow et al. | Jun 2001 | B1 |
| 6255708 | Sudharsanan et al. | Jul 2001 | B1 |
| 6256523 | Diab et al. | Jul 2001 | B1 |
| 6263222 | Diab et al. | Jul 2001 | B1 |
| 6278522 | Lepper, Jr. et al. | Aug 2001 | B1 |
| 6280213 | Tobler et al. | Aug 2001 | B1 |
| 6280381 | Malin et al. | Aug 2001 | B1 |
| 6285896 | Tobler et al. | Sep 2001 | B1 |
| 6301493 | Marro et al. | Oct 2001 | B1 |
| 6308089 | von der Ruhr et al. | Oct 2001 | B1 |
| 6317627 | Ennen et al. | Nov 2001 | B1 |
| 6321100 | Parker | Nov 2001 | B1 |
| 6325761 | Jay | Dec 2001 | B1 |
| 6334065 | Al-Ali et al. | Dec 2001 | B1 |
| 6343224 | Parker | Jan 2002 | B1 |
| 6349228 | Kiani et al. | Feb 2002 | B1 |
| 6360114 | Diab et al. | Mar 2002 | B1 |
| 6368283 | Xu et al. | Apr 2002 | B1 |
| 6371921 | Caro et al. | Apr 2002 | B1 |
| 6377829 | Al-Ali | Apr 2002 | B1 |
| 6388240 | Schulz et al. | May 2002 | B2 |
| 6397091 | Diab et al. | May 2002 | B2 |
| 6411373 | Garside et al. | Jun 2002 | B1 |
| 6415167 | Blank et al. | Jul 2002 | B1 |
| 6430437 | Marro | Aug 2002 | B1 |
| 6430525 | Weber et al. | Aug 2002 | B1 |
| 6463311 | Diab | Oct 2002 | B1 |
| 6470199 | Kopotic et al. | Oct 2002 | B1 |
| 6487429 | Hockersmith et al. | Nov 2002 | B2 |
| 6501975 | Diab et al. | Dec 2002 | B2 |
| 6505059 | Kollias et al. | Jan 2003 | B1 |
| 6515273 | Al-Ali | Feb 2003 | B2 |
| 6519487 | Parker | Feb 2003 | B1 |
| 6525386 | Mills et al. | Feb 2003 | B1 |
| 6526300 | Kiani et al. | Feb 2003 | B1 |
| 6534012 | Hazen et al. | Mar 2003 | B1 |
| 6541756 | Schulz et al. | Apr 2003 | B2 |
| 6542764 | Al-Ali et al. | Apr 2003 | B1 |
| 6580086 | Schulz et al. | Jun 2003 | B1 |
| 6584336 | Ali et al. | Jun 2003 | B1 |
| 6587196 | Stippick et al. | Jul 2003 | B1 |
| 6587199 | Luu | Jul 2003 | B1 |
| 6595316 | Cybulski et al. | Jul 2003 | B2 |
| 6597932 | Tian et al. | Jul 2003 | B2 |
| 6597933 | Kiani et al. | Jul 2003 | B2 |
| 6606511 | Ali et al. | Aug 2003 | B1 |
| 6611206 | Eshelman et al. | Aug 2003 | B2 |
| 6611707 | Prausnitz et al. | Aug 2003 | B1 |
| 6632181 | Flaherty et al. | Oct 2003 | B2 |
| 6635559 | Greenwald et al. | Oct 2003 | B2 |
| 6639668 | Trepagnier | Oct 2003 | B1 |
| 6640116 | Diab | Oct 2003 | B2 |
| 6640117 | Makarewicz et al. | Oct 2003 | B2 |
| 6643530 | Diab et al. | Nov 2003 | B2 |
| 6650917 | Diab et al. | Nov 2003 | B2 |
| 6654624 | Diab et al. | Nov 2003 | B2 |
| 6658276 | Kiani et al. | Dec 2003 | B2 |
| 6661161 | Lanzo et al. | Dec 2003 | B1 |
| 6671531 | Al-Ali | Dec 2003 | B2 |
| 6678543 | Diab et al. | Jan 2004 | B2 |
| 6684090 | Ali et al. | Jan 2004 | B2 |
| 6684091 | Parker | Jan 2004 | B2 |
| 6697656 | Al-Ali | Feb 2004 | B1 |
| 6697657 | Shehada et al. | Feb 2004 | B1 |
| 6697658 | Al-Ali | Feb 2004 | B2 |
| RE38476 | Diab et al. | Mar 2004 | E |
| 6699194 | Diab et al. | Mar 2004 | B1 |
| 6714804 | Al-Ali et al. | Mar 2004 | B2 |
| RE38492 | Diab et al. | Apr 2004 | E |
| 6721582 | Trepagnier et al. | Apr 2004 | B2 |
| 6721585 | Parker | Apr 2004 | B1 |
| 6723046 | Lichtenstein | Apr 2004 | B2 |
| 6725075 | Al-Ali | Apr 2004 | B2 |
| 6728560 | Kollias et al. | Apr 2004 | B2 |
| 6735459 | Parker | May 2004 | B2 |
| 6738652 | Mattu et al. | May 2004 | B2 |
| 6745060 | Diab et al. | Jun 2004 | B2 |
| 6760607 | Al-Ali | Jul 2004 | B2 |
| 6767341 | Cho | Jul 2004 | B2 |
| 6770028 | Ali et al. | Aug 2004 | B1 |
| 6771994 | Kiani et al. | Aug 2004 | B2 |
| 6788965 | Ruchti et al. | Sep 2004 | B2 |
| 6792300 | Diab et al. | Sep 2004 | B1 |
| 6813511 | Diab et al. | Nov 2004 | B2 |
| 6816241 | Grubisic | Nov 2004 | B2 |
| 6816741 | Diab | Nov 2004 | B2 |
| 6822564 | Al-Ali | Nov 2004 | B2 |
| 6826419 | Diab et al. | Nov 2004 | B2 |
| 6830711 | Mills et al. | Dec 2004 | B2 |
| 6850787 | Weber et al. | Feb 2005 | B2 |
| 6850788 | Al-Ali | Feb 2005 | B2 |
| 6852083 | Caro et al. | Feb 2005 | B2 |
| 6861639 | Al-Ali | Mar 2005 | B2 |
| 6876931 | Lorenz et al. | Apr 2005 | B2 |
| 6898452 | Al-Ali et al. | May 2005 | B2 |
| 6920345 | Al-Ali et al. | Jul 2005 | B2 |
| 6931268 | Kiani-Azarbayjany et al. | Aug 2005 | B1 |
| 6934570 | Kiani et al. | Aug 2005 | B2 |
| 6936007 | Quy | Aug 2005 | B2 |
| 6939305 | Flaherty et al. | Sep 2005 | B2 |
| 6943348 | Coffin, IV | Sep 2005 | B1 |
| 6950687 | Al-Ali | Sep 2005 | B2 |
| 6956649 | Acosta et al. | Oct 2005 | B2 |
| 6961598 | Diab | Nov 2005 | B2 |
| 6970792 | Diab | Nov 2005 | B1 |
| 6976958 | Quy | Dec 2005 | B2 |
| 6979812 | Al-Ali | Dec 2005 | B2 |
| 6985524 | Borchers | Jan 2006 | B1 |
| 6985764 | Mason et al. | Jan 2006 | B2 |
| 6990364 | Ruchti et al. | Jan 2006 | B2 |
| 6993371 | Kiani et al. | Jan 2006 | B2 |
| 6996427 | Ali et al. | Feb 2006 | B2 |
| 6998247 | Monfre et al. | Feb 2006 | B2 |
| 6999904 | Weber et al. | Feb 2006 | B2 |
| 7003338 | Weber et al. | Feb 2006 | B2 |
| 7003339 | Diab et al. | Feb 2006 | B2 |
| 7015451 | Dalke et al. | Mar 2006 | B2 |
| 7024233 | Ali et al. | Apr 2006 | B2 |
| 7027849 | Al-Ali | Apr 2006 | B2 |
| 7030749 | Al-Ali | Apr 2006 | B2 |
| 7039449 | Al-Ali | May 2006 | B2 |
| 7041060 | Flaherty et al. | May 2006 | B2 |
| 7044918 | Diab | May 2006 | B2 |
| 7048687 | Reuss et al. | May 2006 | B1 |
| 7067893 | Mills et al. | Jun 2006 | B2 |
| D526719 | Richie, Jr. et al. | Aug 2006 | S |
| 7096052 | Mason et al. | Aug 2006 | B2 |
| 7096054 | Abdul-Hafiz et al. | Aug 2006 | B2 |
| D529616 | Deros et al. | Oct 2006 | S |
| 7132641 | Schulz et al. | Nov 2006 | B2 |
| 7133710 | Acosta et al. | Nov 2006 | B2 |
| 7142901 | Kiani et al. | Nov 2006 | B2 |
| 7149561 | Diab | Dec 2006 | B2 |
| 7156809 | Quy | Jan 2007 | B2 |
| 7186966 | Al-Ali | Mar 2007 | B2 |
| 7190261 | Al-Ali | Mar 2007 | B2 |
| 7215984 | Diab et al. | May 2007 | B2 |
| 7215986 | Diab et al. | May 2007 | B2 |
| 7220000 | Alster | May 2007 | B2 |
| 7221971 | Diab et al. | May 2007 | B2 |
| 7225006 | Al-Ali et al. | May 2007 | B2 |
| 7225007 | Al-Ali et al. | May 2007 | B2 |
| RE39672 | Shehada et al. | Jun 2007 | E |
| 7239905 | Kiani-Azarbayjany et al. | Jul 2007 | B2 |
| 7245953 | Parker | Jul 2007 | B1 |
| 7254429 | Schurman et al. | Aug 2007 | B2 |
| 7254431 | Al-Ali et al. | Aug 2007 | B2 |
| 7254433 | Diab et al. | Aug 2007 | B2 |
| 7254434 | Schulz et al. | Aug 2007 | B2 |
| 7272425 | Al-Ali | Sep 2007 | B2 |
| 7274955 | Kiani et al. | Sep 2007 | B2 |
| D554263 | Al-Ali et al. | Oct 2007 | S |
| 7280858 | Al-Ali et al. | Oct 2007 | B2 |
| 7289835 | Mansfield et al. | Oct 2007 | B2 |
| 7292883 | De Felice et al. | Nov 2007 | B2 |
| 7295866 | Al-Ali | Nov 2007 | B2 |
| 7328053 | Diab et al. | Feb 2008 | B1 |
| 7332784 | Mills et al. | Feb 2008 | B2 |
| 7340287 | Mason et al. | Mar 2008 | B2 |
| 7341559 | Schulz et al. | Mar 2008 | B2 |
| 7343186 | Lamego et al. | Mar 2008 | B2 |
| D566282 | Al-Ali et al. | Apr 2008 | S |
| 7355512 | Al-Ali | Apr 2008 | B1 |
| 7356365 | Schurman | Apr 2008 | B2 |
| 7371981 | Abdul-Hafiz | May 2008 | B2 |
| 7373193 | Al-Ali et al. | May 2008 | B2 |
| 7373194 | Weber et al. | May 2008 | B2 |
| 7376453 | Diab et al. | May 2008 | B1 |
| 7377794 | Al-Ali et al. | May 2008 | B2 |
| 7377899 | Weber et al. | May 2008 | B2 |
| 7383070 | Diab et al. | Jun 2008 | B2 |
| 7395158 | Monfre et al. | Jul 2008 | B2 |
| 7415297 | Al-Ali et al. | Aug 2008 | B2 |
| 7428432 | Ali et al. | Sep 2008 | B2 |
| 7438683 | Al-Ali et al. | Oct 2008 | B2 |
| 7440787 | Diab | Oct 2008 | B2 |
| 7454240 | Diab et al. | Nov 2008 | B2 |
| 7467002 | Weber et al. | Dec 2008 | B2 |
| 7469157 | Diab et al. | Dec 2008 | B2 |
| 7471969 | Diab et al. | Dec 2008 | B2 |
| 7471971 | Diab et al. | Dec 2008 | B2 |
| 7483729 | Al-Ali et al. | Jan 2009 | B2 |
| 7483730 | Diab et al. | Jan 2009 | B2 |
| 7489958 | Diab et al. | Feb 2009 | B2 |
| 7496391 | Diab et al. | Feb 2009 | B2 |
| 7496393 | Diab et al. | Feb 2009 | B2 |
| D587657 | Al-Ali et al. | Mar 2009 | S |
| 7499741 | Diab et al. | Mar 2009 | B2 |
| 7499835 | Weber et al. | Mar 2009 | B2 |
| 7500950 | Al-Ali et al. | Mar 2009 | B2 |
| 7509154 | Diab et al. | Mar 2009 | B2 |
| 7509494 | Al-Ali | Mar 2009 | B2 |
| 7510849 | Schurman et al. | Mar 2009 | B2 |
| 7514725 | Wojtczuk et al. | Apr 2009 | B2 |
| 7519406 | Blank et al. | Apr 2009 | B2 |
| 7526328 | Diab et al. | Apr 2009 | B2 |
| D592507 | Wachman et al. | May 2009 | S |
| 7530942 | Diab | May 2009 | B1 |
| 7530949 | Al Ali et al. | May 2009 | B2 |
| 7530955 | Diab et al. | May 2009 | B2 |
| 7563110 | Al-Ali et al. | Jul 2009 | B2 |
| 7593230 | Abul-Haj et al. | Sep 2009 | B2 |
| 7596398 | Al-Ali et al. | Sep 2009 | B2 |
| 7606608 | Blank et al. | Oct 2009 | B2 |
| 7618375 | Flaherty et al. | Nov 2009 | B2 |
| 7620674 | Ruchti et al. | Nov 2009 | B2 |
| D606659 | Kiani et al. | Dec 2009 | S |
| 7629039 | Eckerbom et al. | Dec 2009 | B2 |
| 7640140 | Ruchti et al. | Dec 2009 | B2 |
| 7647083 | Al-Ali et al. | Jan 2010 | B2 |
| D609193 | Al-Ali et al. | Feb 2010 | S |
| D614305 | Al-Ali et al. | Apr 2010 | S |
| 7697966 | Monfre et al. | Apr 2010 | B2 |
| 7698105 | Ruchti et al. | Apr 2010 | B2 |
| RE41317 | Parker | May 2010 | E |
| RE41333 | Blank et al. | May 2010 | E |
| 7729733 | Al-Ali et al. | Jun 2010 | B2 |
| 7733224 | Tran | Jun 2010 | B2 |
| 7734320 | Al-Ali | Jun 2010 | B2 |
| 7761127 | Al-Ali et al. | Jul 2010 | B2 |
| 7761128 | Al-Ali et al. | Jul 2010 | B2 |
| 7764982 | Dalke et al. | Jul 2010 | B2 |
| D621516 | Kiani et al. | Aug 2010 | S |
| 7791155 | Diab | Sep 2010 | B2 |
| 7801581 | Diab | Sep 2010 | B2 |
| 7822452 | Schurman et al. | Oct 2010 | B2 |
| RE41912 | Parker | Nov 2010 | E |
| 7839266 | Hoglund et al. | Nov 2010 | B2 |
| 7844313 | Kiani et al. | Nov 2010 | B2 |
| 7844314 | Al-Ali | Nov 2010 | B2 |
| 7844315 | Al-Ali | Nov 2010 | B2 |
| 7865222 | Weber et al. | Jan 2011 | B2 |
| 7873497 | Weber et al. | Jan 2011 | B2 |
| 7880606 | Al-Ali | Feb 2011 | B2 |
| 7880626 | Al-Ali et al. | Feb 2011 | B2 |
| 7891355 | Al-Ali et al. | Feb 2011 | B2 |
| 7894868 | Al-Ali et al. | Feb 2011 | B2 |
| 7899507 | Al-Ali et al. | Mar 2011 | B2 |
| 7899518 | Trepagnier et al. | Mar 2011 | B2 |
| 7904132 | Weber et al. | Mar 2011 | B2 |
| 7909772 | Popov et al. | Mar 2011 | B2 |
| 7910875 | Al-Ali | Mar 2011 | B2 |
| 7919713 | Al-Ali et al. | Apr 2011 | B2 |
| 7937128 | Al-Ali | May 2011 | B2 |
| 7937129 | Mason et al. | May 2011 | B2 |
| 7937130 | Diab et al. | May 2011 | B2 |
| 7941199 | Kiani | May 2011 | B2 |
| 7951086 | Flaherty et al. | May 2011 | B2 |
| 7957780 | Lamego et al. | Jun 2011 | B2 |
| 7962188 | Kiani et al. | Jun 2011 | B2 |
| 7962190 | Diab et al. | Jun 2011 | B1 |
| 7976472 | Kiani | Jul 2011 | B2 |
| 7988637 | Diab | Aug 2011 | B2 |
| 7990382 | Kiani | Aug 2011 | B2 |
| 7991446 | Ali et al. | Aug 2011 | B2 |
| 7999685 | Sanchez et al. | Aug 2011 | B2 |
| 8000761 | Al-Ali | Aug 2011 | B2 |
| 8008088 | Bellott et al. | Aug 2011 | B2 |
| RE42753 | Kiani-Azarbayjany et al. | Sep 2011 | E |
| 8019400 | Diab et al. | Sep 2011 | B2 |
| 8028701 | Al-Ali et al. | Oct 2011 | B2 |
| 8029765 | Bellott et al. | Oct 2011 | B2 |
| 8036727 | Schurman et al. | Oct 2011 | B2 |
| 8036728 | Diab et al. | Oct 2011 | B2 |
| 8046040 | Ali et al. | Oct 2011 | B2 |
| 8046041 | Diab et al. | Oct 2011 | B2 |
| 8046042 | Diab et al. | Oct 2011 | B2 |
| 8048040 | Kiani | Nov 2011 | B2 |
| 8050728 | Al-Ali et al. | Nov 2011 | B2 |
| RE43169 | Parker | Feb 2012 | E |
| 8118620 | Al-Ali et al. | Feb 2012 | B2 |
| 8126528 | Diab et al. | Feb 2012 | B2 |
| 8128572 | Diab et al. | Mar 2012 | B2 |
| 8130105 | Al-Ali et al. | Mar 2012 | B2 |
| 8135227 | Lewis | Mar 2012 | B2 |
| 8145287 | Diab et al. | Mar 2012 | B2 |
| 8150487 | Diab et al. | Apr 2012 | B2 |
| 8175672 | Parker | May 2012 | B2 |
| 8180420 | Diab et al. | May 2012 | B2 |
| 8182443 | Kiani | May 2012 | B1 |
| 8185180 | Diab et al. | May 2012 | B2 |
| 8190223 | Al-Ali et al. | May 2012 | B2 |
| 8190227 | Diab et al. | May 2012 | B2 |
| 8203438 | Kiani et al. | Jun 2012 | B2 |
| 8203704 | Merritt et al. | Jun 2012 | B2 |
| 8204566 | Schurman et al. | Jun 2012 | B2 |
| 8219172 | Schurman et al. | Jul 2012 | B2 |
| 8224411 | Al-Ali et al. | Jul 2012 | B2 |
| 8228181 | Al-Ali | Jul 2012 | B2 |
| 8229532 | Davis | Jul 2012 | B2 |
| 8229533 | Diab et al. | Jul 2012 | B2 |
| 8233955 | Al-Ali et al. | Jul 2012 | B2 |
| 8244325 | Al-Ali et al. | Aug 2012 | B2 |
| 8255026 | Al-Ali | Aug 2012 | B1 |
| 8255027 | Al-Ali et al. | Aug 2012 | B2 |
| 8255028 | Al-Ali et al. | Aug 2012 | B2 |
| 8260577 | Weber et al. | Sep 2012 | B2 |
| 8265723 | McHale et al. | Sep 2012 | B1 |
| 8274360 | Sampath et al. | Sep 2012 | B2 |
| 8280473 | Al-Ali | Oct 2012 | B2 |
| 8301217 | Al-Ali et al. | Oct 2012 | B2 |
| 8306596 | Schurman et al. | Nov 2012 | B2 |
| 8310336 | Muhsin et al. | Nov 2012 | B2 |
| 8315683 | Al-Ali et al. | Nov 2012 | B2 |
| RE43860 | Parker | Dec 2012 | E |
| 8337403 | Al-Ali et al. | Dec 2012 | B2 |
| 8346330 | Lamego | Jan 2013 | B2 |
| 8353842 | Al-Ali et al. | Jan 2013 | B2 |
| 8355766 | MacNeish, III et al. | Jan 2013 | B2 |
| 8359080 | Diab et al. | Jan 2013 | B2 |
| 8364223 | Al-Ali et al. | Jan 2013 | B2 |
| 8364226 | Diab et al. | Jan 2013 | B2 |
| 8374665 | Lamego | Feb 2013 | B2 |
| 8385995 | Al-Ali et al. | Feb 2013 | B2 |
| 8385996 | Smith et al. | Feb 2013 | B2 |
| 8388353 | Kiani et al. | Mar 2013 | B2 |
| 8390694 | Ryan et al. | Mar 2013 | B2 |
| 8399822 | Al-Ali | Mar 2013 | B2 |
| 8401602 | Kiani | Mar 2013 | B2 |
| 8405608 | Al-Ali et al. | Mar 2013 | B2 |
| 8414499 | Al-Ali et al. | Apr 2013 | B2 |
| 8418524 | Al-Ali | Apr 2013 | B2 |
| 8423106 | Lamego et al. | Apr 2013 | B2 |
| 8428967 | Olsen et al. | Apr 2013 | B2 |
| 8430817 | Al-Ali et al. | Apr 2013 | B1 |
| 8437825 | Dalvi et al. | May 2013 | B2 |
| 8455290 | Siskavich | Jun 2013 | B2 |
| 8457703 | Al-Ali | Jun 2013 | B2 |
| 8457707 | Kiani | Jun 2013 | B2 |
| 8463349 | Diab et al. | Jun 2013 | B2 |
| 8466286 | Bellott et al. | Jun 2013 | B2 |
| 8471713 | Poeze et al. | Jun 2013 | B2 |
| 8473020 | Kiani et al. | Jun 2013 | B2 |
| 8483787 | Al-Ali et al. | Jul 2013 | B2 |
| 8489364 | Weber et al. | Jul 2013 | B2 |
| 8498684 | Weber et al. | Jul 2013 | B2 |
| 8504128 | Blank et al. | Aug 2013 | B2 |
| 8509867 | Workman et al. | Aug 2013 | B2 |
| 8515509 | Bruinsma et al. | Aug 2013 | B2 |
| 8523781 | Al-Ali | Sep 2013 | B2 |
| 8529301 | Al-Ali et al. | Sep 2013 | B2 |
| 8532727 | Ali et al. | Sep 2013 | B2 |
| 8532728 | Diab et al. | Sep 2013 | B2 |
| D692145 | Al-Ali et al. | Oct 2013 | S |
| 8547209 | Kiani et al. | Oct 2013 | B2 |
| 8548548 | Al-Ali | Oct 2013 | B2 |
| 8548549 | Schurman et al. | Oct 2013 | B2 |
| 8548550 | Al-Ali et al. | Oct 2013 | B2 |
| 8560032 | Al-Ali et al. | Oct 2013 | B2 |
| 8560034 | Diab et al. | Oct 2013 | B1 |
| 8570167 | Al-Ali | Oct 2013 | B2 |
| 8570503 | Vo et al. | Oct 2013 | B2 |
| 8571617 | Reichgott et al. | Oct 2013 | B2 |
| 8571618 | Lamego et al. | Oct 2013 | B1 |
| 8571619 | Al-Ali et al. | Oct 2013 | B2 |
| 8577431 | Lamego et al. | Nov 2013 | B2 |
| 8581732 | Al-Ali et al. | Nov 2013 | B2 |
| 8584345 | Al-Ali et al. | Nov 2013 | B2 |
| 8588880 | Abdul-Hafiz et al. | Nov 2013 | B2 |
| 8591430 | Amurthur et al. | Nov 2013 | B2 |
| 8600467 | Al-Ali et al. | Dec 2013 | B2 |
| 8603384 | Luttge et al. | Dec 2013 | B2 |
| 8606342 | Diab | Dec 2013 | B2 |
| 8615408 | Ryan | Dec 2013 | B2 |
| 8622922 | Banet et al. | Jan 2014 | B2 |
| 8626255 | Al-Ali et al. | Jan 2014 | B2 |
| 8630691 | Lamego et al. | Jan 2014 | B2 |
| 8634889 | Al-Ali et al. | Jan 2014 | B2 |
| 8641631 | Sierra et al. | Feb 2014 | B2 |
| 8652060 | Al-Ali | Feb 2014 | B2 |
| 8663107 | Kiani | Mar 2014 | B2 |
| 8666468 | Al-Ali | Mar 2014 | B1 |
| 8667967 | Al-Ali et al. | Mar 2014 | B2 |
| 8670811 | O'Reilly | Mar 2014 | B2 |
| 8670814 | Diab et al. | Mar 2014 | B2 |
| 8676286 | Weber et al. | Mar 2014 | B2 |
| 8682407 | Al-Ali | Mar 2014 | B2 |
| RE44823 | Parker | Apr 2014 | E |
| RE44875 | Kiani et al. | Apr 2014 | E |
| 8688183 | Bruinsma et al. | Apr 2014 | B2 |
| 8690799 | Telfort et al. | Apr 2014 | B2 |
| 8700112 | Kiani | Apr 2014 | B2 |
| 8702627 | Telfort et al. | Apr 2014 | B2 |
| 8706179 | Parker | Apr 2014 | B2 |
| 8712494 | MacNeish, III et al. | Apr 2014 | B1 |
| 8715206 | Telfort et al. | May 2014 | B2 |
| 8718735 | Lamego et al. | May 2014 | B2 |
| 8718737 | Diab et al. | May 2014 | B2 |
| 8718738 | Blank et al. | May 2014 | B2 |
| 8720249 | Al-Ali | May 2014 | B2 |
| 8721541 | Al-Ali et al. | May 2014 | B2 |
| 8721542 | Al-Ali et al. | May 2014 | B2 |
| 8723677 | Kiani | May 2014 | B1 |
| 8740792 | Kiani et al. | Jun 2014 | B1 |
| 8754776 | Poeze et al. | Jun 2014 | B2 |
| 8755535 | Telfort et al. | Jun 2014 | B2 |
| 8755856 | Diab et al. | Jun 2014 | B2 |
| 8755872 | Marinow | Jun 2014 | B1 |
| 8761850 | Lamego | Jun 2014 | B2 |
| 8764671 | Kiani | Jul 2014 | B2 |
| 8768423 | Shakespeare et al. | Jul 2014 | B2 |
| 8771204 | Telfort et al. | Jul 2014 | B2 |
| 8777634 | Kiani et al. | Jul 2014 | B2 |
| 8781543 | Diab et al. | Jul 2014 | B2 |
| 8781544 | Al-Ali et al. | Jul 2014 | B2 |
| 8781549 | Al-Ali et al. | Jul 2014 | B2 |
| 8788003 | Schurman et al. | Jul 2014 | B2 |
| 8790268 | Al-Ali | Jul 2014 | B2 |
| 8801613 | Al-Ali et al. | Aug 2014 | B2 |
| 8821397 | Al-Ali et al. | Sep 2014 | B2 |
| 8821415 | Al-Ali et al. | Sep 2014 | B2 |
| 8830449 | Lamego et al. | Sep 2014 | B1 |
| 8831700 | Schurman et al. | Sep 2014 | B2 |
| 8840549 | Al-Ali et al. | Sep 2014 | B2 |
| 8847740 | Kiani et al. | Sep 2014 | B2 |
| 8849365 | Smith et al. | Sep 2014 | B2 |
| 8852094 | Al-Ali et al. | Oct 2014 | B2 |
| 8852994 | Wojtczuk et al. | Oct 2014 | B2 |
| 8868147 | Stippick et al. | Oct 2014 | B2 |
| 8868150 | Al-Ali et al. | Oct 2014 | B2 |
| 8870792 | Al-Ali et al. | Oct 2014 | B2 |
| 8886271 | Kiani et al. | Nov 2014 | B2 |
| 8888539 | Al-Ali et al. | Nov 2014 | B2 |
| 8888708 | Diab et al. | Nov 2014 | B2 |
| 8892180 | Weber et al. | Nov 2014 | B2 |
| 8897847 | Al-Ali | Nov 2014 | B2 |
| 8909310 | Lamego et al. | Dec 2014 | B2 |
| 8911377 | Al-Ali | Dec 2014 | B2 |
| 8912909 | Al-Ali et al. | Dec 2014 | B2 |
| 8920317 | Al-Ali et al. | Dec 2014 | B2 |
| 8921699 | Al-Ali et al. | Dec 2014 | B2 |
| 8922382 | Al-Ali et al. | Dec 2014 | B2 |
| 8929964 | Al-Ali et al. | Jan 2015 | B2 |
| 8942777 | Diab et al. | Jan 2015 | B2 |
| 8948834 | Diab et al. | Feb 2015 | B2 |
| 8948835 | Diab | Feb 2015 | B2 |
| 8965471 | Lamego | Feb 2015 | B2 |
| 8968195 | Tran | Mar 2015 | B2 |
| 8983564 | Al-Ali | Mar 2015 | B2 |
| 8989831 | Al-Ali et al. | Mar 2015 | B2 |
| 8996085 | Kiani et al. | Mar 2015 | B2 |
| 8998809 | Kiani | Apr 2015 | B2 |
| 9028429 | Telfort et al. | May 2015 | B2 |
| 9037207 | Al-Ali et al. | May 2015 | B2 |
| 9060721 | Reichgott et al. | Jun 2015 | B2 |
| 9066666 | Kiani | Jun 2015 | B2 |
| 9066680 | Al-Ali et al. | Jun 2015 | B1 |
| 9072474 | Al-Ali et al. | Jul 2015 | B2 |
| 9078560 | Schurman et al. | Jul 2015 | B2 |
| 9084569 | Weber et al. | Jul 2015 | B2 |
| 9095316 | Welch et al. | Aug 2015 | B2 |
| 9106038 | Telfort et al. | Aug 2015 | B2 |
| 9107625 | Telfort et al. | Aug 2015 | B2 |
| 9107626 | Al-Ali et al. | Aug 2015 | B2 |
| 9113831 | Al-Ali | Aug 2015 | B2 |
| 9113832 | Al-Ali | Aug 2015 | B2 |
| 9119595 | Lamego | Sep 2015 | B2 |
| 9131881 | Diab et al. | Sep 2015 | B2 |
| 9131882 | Al-Ali et al. | Sep 2015 | B2 |
| 9131883 | Al-Ali | Sep 2015 | B2 |
| 9131917 | Telfort et al. | Sep 2015 | B2 |
| 9138180 | Coverston et al. | Sep 2015 | B1 |
| 9138182 | Al-Ali et al. | Sep 2015 | B2 |
| 9138192 | Weber et al. | Sep 2015 | B2 |
| 9142117 | Muhsin et al. | Sep 2015 | B2 |
| 9153112 | Kiani et al. | Oct 2015 | B1 |
| 9153121 | Kiani et al. | Oct 2015 | B2 |
| 9161696 | Al-Ali et al. | Oct 2015 | B2 |
| 9161713 | Al-Ali et al. | Oct 2015 | B2 |
| 9167995 | Lamego et al. | Oct 2015 | B2 |
| 9176141 | Al-Ali et al. | Nov 2015 | B2 |
| 9186075 | Baker, Jr. et al. | Nov 2015 | B2 |
| 9186102 | Bruinsma et al. | Nov 2015 | B2 |
| 9192312 | Al-Ali | Nov 2015 | B2 |
| 9192329 | Al-Ali | Nov 2015 | B2 |
| 9192351 | Telfort et al. | Nov 2015 | B1 |
| 9195385 | Al-Ali et al. | Nov 2015 | B2 |
| 9211072 | Kiani | Dec 2015 | B2 |
| 9211095 | Al-Ali | Dec 2015 | B1 |
| 9218454 | Kiani et al. | Dec 2015 | B2 |
| 9226696 | Kiani | Jan 2016 | B2 |
| 9241662 | Al-Ali et al. | Jan 2016 | B2 |
| 9245668 | Vo et al. | Jan 2016 | B1 |
| 9259185 | Abdul-Hafiz et al. | Feb 2016 | B2 |
| 9267572 | Barker et al. | Feb 2016 | B2 |
| 9277880 | Poeze et al. | Mar 2016 | B2 |
| 9283150 | Bujalski et al. | Mar 2016 | B2 |
| 9289167 | Diab et al. | Mar 2016 | B2 |
| 9295421 | Kiani et al. | Mar 2016 | B2 |
| 9307928 | Al-Ali et al. | Apr 2016 | B1 |
| 9323894 | Kiani | Apr 2016 | B2 |
| D755392 | Hwang et al. | May 2016 | S |
| 9326712 | Kiani | May 2016 | B1 |
| 9333316 | Kiani | May 2016 | B2 |
| 9339220 | Lamego et al. | May 2016 | B2 |
| 9341565 | Lamego et al. | May 2016 | B2 |
| 9351673 | Diab et al. | May 2016 | B2 |
| 9351675 | Al-Ali et al. | May 2016 | B2 |
| 9364181 | Kiani et al. | Jun 2016 | B2 |
| 9368671 | Wojtczuk et al. | Jun 2016 | B2 |
| 9370325 | Al-Ali et al. | Jun 2016 | B2 |
| 9370326 | McHale et al. | Jun 2016 | B2 |
| 9370335 | Al-Ali et al. | Jun 2016 | B2 |
| 9375185 | Ali et al. | Jun 2016 | B2 |
| 9386953 | Al-Ali | Jul 2016 | B2 |
| 9386961 | Al-Ali et al. | Jul 2016 | B2 |
| 9392945 | Al-Ali et al. | Jul 2016 | B2 |
| 9397448 | Al-Ali et al. | Jul 2016 | B2 |
| 9405135 | Sweis | Aug 2016 | B2 |
| 9408542 | Kinast et al. | Aug 2016 | B1 |
| 9436645 | Al-Ali et al. | Sep 2016 | B2 |
| 9445759 | Lamego et al. | Sep 2016 | B1 |
| 9466919 | Kiani et al. | Oct 2016 | B2 |
| 9474474 | Lamego et al. | Oct 2016 | B2 |
| 9480422 | Al-Ali | Nov 2016 | B2 |
| 9480435 | Olsen | Nov 2016 | B2 |
| 9492110 | Al-Ali et al. | Nov 2016 | B2 |
| 9510779 | Poeze et al. | Dec 2016 | B2 |
| 9517024 | Kiani et al. | Dec 2016 | B2 |
| 9532722 | Lamego et al. | Jan 2017 | B2 |
| 9538949 | Al-Ali et al. | Jan 2017 | B2 |
| 9538980 | Telfort et al. | Jan 2017 | B2 |
| 9549696 | Lamego et al. | Jan 2017 | B2 |
| 9554706 | Soomro et al. | Jan 2017 | B2 |
| 9554737 | Schurman et al. | Jan 2017 | B2 |
| 9560996 | Kiani | Feb 2017 | B2 |
| 9560998 | Al-Ali et al. | Feb 2017 | B2 |
| 9566019 | Al-Ali et al. | Feb 2017 | B2 |
| 9579039 | Jansen et al. | Feb 2017 | B2 |
| 9591975 | Dalvi et al. | Mar 2017 | B2 |
| 9597004 | Hughes et al. | Mar 2017 | B2 |
| 9615792 | Raptis et al. | Apr 2017 | B2 |
| 9622692 | Lamego et al. | Apr 2017 | B2 |
| 9622693 | Diab | Apr 2017 | B2 |
| D788312 | Al-Ali et al. | May 2017 | S |
| 9636055 | Al Ali et al. | May 2017 | B2 |
| 9636056 | Al-Ali | May 2017 | B2 |
| 9649054 | Lamego et al. | May 2017 | B2 |
| 9662052 | Al-Ali et al. | May 2017 | B2 |
| 9668679 | Schurman et al. | Jun 2017 | B2 |
| 9668680 | Bruinsma et al. | Jun 2017 | B2 |
| 9668703 | Al-Ali | Jun 2017 | B2 |
| 9675286 | Diab | Jun 2017 | B2 |
| 9687160 | Kiani | Jun 2017 | B2 |
| 9693719 | Al-Ali et al. | Jul 2017 | B2 |
| 9693737 | Al-Ali | Jul 2017 | B2 |
| 9697928 | Al-Ali et al. | Jul 2017 | B2 |
| 9700222 | Quinlan et al. | Jul 2017 | B2 |
| 9717425 | Kiani et al. | Aug 2017 | B2 |
| 9717458 | Lamego et al. | Aug 2017 | B2 |
| 9724016 | Al-Ali et al. | Aug 2017 | B1 |
| 9724024 | Al-Ali | Aug 2017 | B2 |
| 9724025 | Kiani et al. | Aug 2017 | B1 |
| 9730640 | Diab et al. | Aug 2017 | B2 |
| 9743887 | Al-Ali et al. | Aug 2017 | B2 |
| 9749232 | Sampath et al. | Aug 2017 | B2 |
| 9750442 | Olsen | Sep 2017 | B2 |
| 9750443 | Smith et al. | Sep 2017 | B2 |
| 9750461 | Telfort | Sep 2017 | B1 |
| 9775545 | Al-Ali et al. | Oct 2017 | B2 |
| 9775546 | Diab et al. | Oct 2017 | B2 |
| 9775570 | Al-Ali | Oct 2017 | B2 |
| 9778079 | Al-Ali et al. | Oct 2017 | B1 |
| 9782077 | Lamego et al. | Oct 2017 | B2 |
| 9782110 | Kiani | Oct 2017 | B2 |
| 9787568 | Lamego et al. | Oct 2017 | B2 |
| 9788735 | Al-Ali | Oct 2017 | B2 |
| 9788768 | Al-Ali et al. | Oct 2017 | B2 |
| 9795300 | Al-Ali | Oct 2017 | B2 |
| 9795310 | Al-Ali | Oct 2017 | B2 |
| 9795358 | Telfort et al. | Oct 2017 | B2 |
| 9795739 | Al-Ali et al. | Oct 2017 | B2 |
| 9801556 | Kiani | Oct 2017 | B2 |
| 9801588 | Weber et al. | Oct 2017 | B2 |
| 9808188 | Perea et al. | Nov 2017 | B1 |
| 9814418 | Weber et al. | Nov 2017 | B2 |
| 9820691 | Kiani | Nov 2017 | B2 |
| 9820699 | Bingley et al. | Nov 2017 | B2 |
| 9833152 | Kiani et al. | Dec 2017 | B2 |
| 9833180 | Shakespeare et al. | Dec 2017 | B2 |
| 9839379 | Al-Ali et al. | Dec 2017 | B2 |
| 9839381 | Weber et al. | Dec 2017 | B1 |
| 9847002 | Kiani et al. | Dec 2017 | B2 |
| 9847749 | Kiani et al. | Dec 2017 | B2 |
| 9848800 | Lee et al. | Dec 2017 | B1 |
| 9848806 | Al-Ali | Dec 2017 | B2 |
| 9848807 | Lamego | Dec 2017 | B2 |
| 9861298 | Eckerbom et al. | Jan 2018 | B2 |
| 9861304 | Al-Ali et al. | Jan 2018 | B2 |
| 9861305 | Weber et al. | Jan 2018 | B1 |
| 9867578 | Al-Ali et al. | Jan 2018 | B2 |
| 9872623 | Al-Ali | Jan 2018 | B2 |
| 9876320 | Coverston et al. | Jan 2018 | B2 |
| 9877650 | Muhsin et al. | Jan 2018 | B2 |
| 9877686 | Al-Ali et al. | Jan 2018 | B2 |
| 9887650 | Maekawa et al. | Feb 2018 | B2 |
| 9891079 | Dalvi | Feb 2018 | B2 |
| 9895107 | Al-Ali et al. | Feb 2018 | B2 |
| 9913617 | Al-Ali et al. | Mar 2018 | B2 |
| 9924893 | Schurman et al. | Mar 2018 | B2 |
| 9924897 | Abdul-Hafiz | Mar 2018 | B1 |
| 9936917 | Poeze et al. | Apr 2018 | B2 |
| 9943269 | Muhsin et al. | Apr 2018 | B2 |
| 9949676 | Al-Ali | Apr 2018 | B2 |
| 9955937 | Telfort | May 2018 | B2 |
| 9965946 | Al-Ali et al. | May 2018 | B2 |
| 9980667 | Kiani et al. | May 2018 | B2 |
| D820865 | Muhsin et al. | Jun 2018 | S |
| 9986919 | Lamego et al. | Jun 2018 | B2 |
| 9986952 | Dalvi et al. | Jun 2018 | B2 |
| 9989560 | Poeze et al. | Jun 2018 | B2 |
| 9993207 | Al-Ali et al. | Jun 2018 | B2 |
| 10007758 | Al-Ali et al. | Jun 2018 | B2 |
| 10008091 | Mason et al. | Jun 2018 | B2 |
| D822215 | Al-Ali et al. | Jul 2018 | S |
| D822216 | Barker et al. | Jul 2018 | S |
| 10010276 | Al-Ali et al. | Jul 2018 | B2 |
| 10032002 | Kiani et al. | Jul 2018 | B2 |
| 10039445 | Torch | Aug 2018 | B1 |
| 10039482 | Al-Ali et al. | Aug 2018 | B2 |
| 10052037 | Kinast et al. | Aug 2018 | B2 |
| 10058275 | Al-Ali et al. | Aug 2018 | B2 |
| 10064562 | Al-Ali | Sep 2018 | B2 |
| 10086138 | Novak, Jr. | Oct 2018 | B1 |
| 10092200 | Al-Ali et al. | Oct 2018 | B2 |
| 10092249 | Kiani et al. | Oct 2018 | B2 |
| 10098550 | Al-Ali et al. | Oct 2018 | B2 |
| 10098591 | Al-Ali et al. | Oct 2018 | B2 |
| 10098610 | Al-Ali et al. | Oct 2018 | B2 |
| 10111591 | Dyell et al. | Oct 2018 | B2 |
| D833624 | DeJong et al. | Nov 2018 | S |
| 10123726 | Al-Ali et al. | Nov 2018 | B2 |
| 10123729 | Dyell et al. | Nov 2018 | B2 |
| 10130289 | Al-Ali et al. | Nov 2018 | B2 |
| 10130291 | Schurman et al. | Nov 2018 | B2 |
| D835282 | Barker et al. | Dec 2018 | S |
| D835283 | Barker et al. | Dec 2018 | S |
| D835284 | Barker et al. | Dec 2018 | S |
| D835285 | Barker et al. | Dec 2018 | S |
| 10149616 | Al-Ali et al. | Dec 2018 | B2 |
| 10154815 | Al-Ali et al. | Dec 2018 | B2 |
| 10159412 | Lamego et al. | Dec 2018 | B2 |
| 10188296 | Al-Ali et al. | Jan 2019 | B2 |
| 10188331 | Kiani et al. | Jan 2019 | B1 |
| 10188348 | Al-Ali et al. | Jan 2019 | B2 |
| RE47218 | Al-Ali | Feb 2019 | E |
| RE47244 | Kiani et al. | Feb 2019 | E |
| RE47249 | Kiani et al. | Feb 2019 | E |
| 10194847 | Al-Ali | Feb 2019 | B2 |
| 10194848 | Kiani et al. | Feb 2019 | B1 |
| 10201298 | Al-Ali et al. | Feb 2019 | B2 |
| 10205272 | Kiani et al. | Feb 2019 | B2 |
| 10205291 | Scruggs et al. | Feb 2019 | B2 |
| 10213108 | Al-Ali | Feb 2019 | B2 |
| 10219706 | Al-Ali | Mar 2019 | B2 |
| 10219746 | McHale et al. | Mar 2019 | B2 |
| 10226187 | Al-Ali et al. | Mar 2019 | B2 |
| 10226576 | Kiani | Mar 2019 | B2 |
| 10231657 | Al-Ali et al. | Mar 2019 | B2 |
| 10231670 | Blank et al. | Mar 2019 | B2 |
| 10231676 | Al-Ali et al. | Mar 2019 | B2 |
| RE47353 | Kiani et al. | Apr 2019 | E |
| 10251585 | Al-Ali et al. | Apr 2019 | B2 |
| 10251586 | Lamego | Apr 2019 | B2 |
| 10255994 | Sampath et al. | Apr 2019 | B2 |
| 10258265 | Poeze et al. | Apr 2019 | B1 |
| 10258266 | Poeze et al. | Apr 2019 | B1 |
| 10271748 | Al-Ali | Apr 2019 | B2 |
| 10278626 | Schurman et al. | May 2019 | B2 |
| 10278648 | Al-Ali et al. | May 2019 | B2 |
| 10279247 | Kiani | May 2019 | B2 |
| 10292628 | Poeze et al. | May 2019 | B1 |
| 10292657 | Abdul-Hafiz et al. | May 2019 | B2 |
| 10292664 | Al-Ali | May 2019 | B2 |
| 10299708 | Poeze et al. | May 2019 | B1 |
| 10299709 | Perea et al. | May 2019 | B2 |
| 10299720 | Brown et al. | May 2019 | B2 |
| 10305775 | Lamego et al. | May 2019 | B2 |
| 10307111 | Muhsin et al. | Jun 2019 | B2 |
| 10325681 | Sampath et al. | Jun 2019 | B2 |
| 10327337 | Schmidt et al. | Jun 2019 | B2 |
| 10327713 | Barker et al. | Jun 2019 | B2 |
| 10332623 | Edwards | Jun 2019 | B2 |
| 10332630 | Al-Ali | Jun 2019 | B2 |
| 10339500 | Hussam | Jul 2019 | B2 |
| 10383520 | Wojtczuk et al. | Aug 2019 | B2 |
| 10383527 | Al-Ali | Aug 2019 | B2 |
| 10388120 | Muhsin et al. | Aug 2019 | B2 |
| 10405804 | Al-Ali | Sep 2019 | B2 |
| 10413666 | Al-Ali et al. | Sep 2019 | B2 |
| 10420493 | Al-Ali et al. | Sep 2019 | B2 |
| D864120 | Forrest et al. | Oct 2019 | S |
| 10433776 | Al-Ali | Oct 2019 | B2 |
| 10441181 | Telfort et al. | Oct 2019 | B1 |
| 10441196 | Eckerbom et al. | Oct 2019 | B2 |
| 10448844 | Al-Ali et al. | Oct 2019 | B2 |
| 10448871 | Al-Ali et al. | Oct 2019 | B2 |
| 10456038 | Lamego et al. | Oct 2019 | B2 |
| 10463340 | Telfort et al. | Nov 2019 | B2 |
| 10471159 | Lapotko et al. | Nov 2019 | B1 |
| 10505311 | Al-Ali et al. | Dec 2019 | B2 |
| 10524738 | Olsen | Jan 2020 | B2 |
| 10532174 | Al-Ali | Jan 2020 | B2 |
| 10537285 | Shreim et al. | Jan 2020 | B2 |
| 10542903 | Al-Ali et al. | Jan 2020 | B2 |
| 10555678 | Dalvi et al. | Feb 2020 | B2 |
| 10568553 | O'Neil et al. | Feb 2020 | B2 |
| RE47882 | Al-Ali | Mar 2020 | E |
| 10608817 | Haider et al. | Mar 2020 | B2 |
| D880477 | Forrest et al. | Apr 2020 | S |
| 10617302 | Al-Ali et al. | Apr 2020 | B2 |
| 10617335 | Al-Ali et al. | Apr 2020 | B2 |
| 10637181 | Al-Ali et al. | Apr 2020 | B2 |
| D887548 | Abdul-Hafiz et al. | Jun 2020 | S |
| D887549 | Abdul-Hafiz et al. | Jun 2020 | S |
| 10667764 | Ahmed et al. | Jun 2020 | B2 |
| D890708 | Forrest et al. | Jul 2020 | S |
| 10721785 | Al-Ali | Jul 2020 | B2 |
| 10736518 | Al-Ali et al. | Aug 2020 | B2 |
| 10750984 | Pauley et al. | Aug 2020 | B2 |
| D897098 | Al-Ali | Sep 2020 | S |
| 10779098 | Iswanto et al. | Sep 2020 | B2 |
| 10827961 | Iyengar et al. | Nov 2020 | B1 |
| 10828007 | Telfort et al. | Nov 2020 | B1 |
| 10832818 | Muhsin et al. | Nov 2020 | B2 |
| 10849554 | Shreim et al. | Dec 2020 | B2 |
| 10856750 | Indorf et al. | Dec 2020 | B2 |
| D906970 | Forrest et al. | Jan 2021 | S |
| 10916336 | Fiedler et al. | Feb 2021 | B2 |
| 10918281 | Al-Ali et al. | Feb 2021 | B2 |
| 10932705 | Muhsin et al. | Mar 2021 | B2 |
| 10932729 | Kiani et al. | Mar 2021 | B2 |
| 10939878 | Kiani et al. | Mar 2021 | B2 |
| 10956950 | Al-Ali et al. | Mar 2021 | B2 |
| D916135 | Indorf et al. | Apr 2021 | S |
| D917550 | Indorf et al. | Apr 2021 | S |
| D917564 | Indorf et al. | Apr 2021 | S |
| D917704 | Al-Ali et al. | Apr 2021 | S |
| 10987066 | Chandran et al. | Apr 2021 | B2 |
| 10991135 | Al-Ali et al. | Apr 2021 | B2 |
| D919094 | Al-Ali et al. | May 2021 | S |
| D919100 | Al-Ali et al. | May 2021 | S |
| 11006867 | Al-Ali | May 2021 | B2 |
| D921202 | Al-Ali et al. | Jun 2021 | S |
| 11024064 | Muhsin et al. | Jun 2021 | B2 |
| 11026604 | Chen et al. | Jun 2021 | B2 |
| D925597 | Chandran et al. | Jul 2021 | S |
| D927699 | Al-Ali et al. | Aug 2021 | S |
| 11076777 | Lee et al. | Aug 2021 | B2 |
| 11114188 | Poeze et al. | Sep 2021 | B2 |
| D933232 | Al-Ali et al. | Oct 2021 | S |
| 11145408 | Sampath et al. | Oct 2021 | B2 |
| 11147518 | Al-Ali et al. | Oct 2021 | B1 |
| 11185262 | Al-Ali et al. | Nov 2021 | B2 |
| 11191484 | Kiani et al. | Dec 2021 | B2 |
| D946596 | Ahmed | Mar 2022 | S |
| D946597 | Ahmed | Mar 2022 | S |
| D946598 | Ahmed | Mar 2022 | S |
| D946617 | Ahmed | Mar 2022 | S |
| 11272839 | Al-Ali et al. | Mar 2022 | B2 |
| 11285121 | Chang | Mar 2022 | B2 |
| 11289199 | Al-Ali | Mar 2022 | B2 |
| RE49034 | Al-Ali | Apr 2022 | E |
| 11298021 | Muhsin et al. | Apr 2022 | B2 |
| D950580 | Ahmed | May 2022 | S |
| D950599 | Ahmed | May 2022 | S |
| D957648 | Al-Ali | Jul 2022 | S |
| 11389093 | Triman et al. | Jul 2022 | B2 |
| 20010034477 | Mansfield et al. | Oct 2001 | A1 |
| 20010039483 | Brand et al. | Nov 2001 | A1 |
| 20020010401 | Bushmakin et al. | Jan 2002 | A1 |
| 20020022973 | Sun et al. | Feb 2002 | A1 |
| 20020058864 | Mansfield et al. | May 2002 | A1 |
| 20020133080 | Apruzzese et al. | Sep 2002 | A1 |
| 20030013975 | Kiani | Jan 2003 | A1 |
| 20030018243 | Gerhardt et al. | Jan 2003 | A1 |
| 20030144582 | Cohen et al. | Jul 2003 | A1 |
| 20030156288 | Barnum et al. | Aug 2003 | A1 |
| 20030212312 | Coffin, IV et al. | Nov 2003 | A1 |
| 20040106163 | Workman, Jr. et al. | Jun 2004 | A1 |
| 20040106858 | Say et al. | Jun 2004 | A1 |
| 20050055276 | Kiani et al. | Mar 2005 | A1 |
| 20050227929 | Masferrer | Oct 2005 | A1 |
| 20050234317 | Kiani | Oct 2005 | A1 |
| 20060073719 | Kiani | Apr 2006 | A1 |
| 20060140502 | Tseng | Jun 2006 | A1 |
| 20060161054 | Reuss et al. | Jul 2006 | A1 |
| 20060189871 | Al-Ali et al. | Aug 2006 | A1 |
| 20070073116 | Kiani et al. | Mar 2007 | A1 |
| 20070180140 | Welch et al. | Aug 2007 | A1 |
| 20070244377 | Cozad et al. | Oct 2007 | A1 |
| 20070293781 | Sims et al. | Dec 2007 | A1 |
| 20070299694 | Merck | Dec 2007 | A1 |
| 20080008745 | Stinchcomb et al. | Jan 2008 | A1 |
| 20080064965 | Jay et al. | Mar 2008 | A1 |
| 20080094228 | Welch et al. | Apr 2008 | A1 |
| 20080097795 | Sasai et al. | Apr 2008 | A1 |
| 20080221418 | Al-Ali et al. | Sep 2008 | A1 |
| 20090036759 | Ault et al. | Feb 2009 | A1 |
| 20090093687 | Telfort et al. | Apr 2009 | A1 |
| 20090095926 | MacNeish, III | Apr 2009 | A1 |
| 20090247984 | Lamego et al. | Oct 2009 | A1 |
| 20090275813 | Davis | Nov 2009 | A1 |
| 20090275844 | Al-Ali | Nov 2009 | A1 |
| 20100004518 | Vo et al. | Jan 2010 | A1 |
| 20100030040 | Poeze et al. | Feb 2010 | A1 |
| 20100094220 | Mandro | Apr 2010 | A1 |
| 20100099964 | O'Reilly et al. | Apr 2010 | A1 |
| 20100234718 | Sampath et al. | Sep 2010 | A1 |
| 20100270257 | Wachman et al. | Oct 2010 | A1 |
| 20110028806 | Merritt et al. | Feb 2011 | A1 |
| 20110028809 | Goodman | Feb 2011 | A1 |
| 20110040197 | Welch et al. | Feb 2011 | A1 |
| 20110054924 | Mitchell et al. | Mar 2011 | A1 |
| 20110082711 | Poeze et al. | Apr 2011 | A1 |
| 20110087081 | Kiani et al. | Apr 2011 | A1 |
| 20110118561 | Tari et al. | May 2011 | A1 |
| 20110125060 | Telfort et al. | May 2011 | A1 |
| 20110137297 | Kiani et al. | Jun 2011 | A1 |
| 20110137680 | Sweeney | Jun 2011 | A1 |
| 20110172498 | Olsen et al. | Jul 2011 | A1 |
| 20110208015 | Welch et al. | Aug 2011 | A1 |
| 20110230733 | Al-Ali | Sep 2011 | A1 |
| 20120041279 | Freeman et al. | Feb 2012 | A1 |
| 20120101847 | Johnson et al. | Apr 2012 | A1 |
| 20120123231 | O'Reilly | May 2012 | A1 |
| 20120136232 | Jeong et al. | May 2012 | A1 |
| 20120165629 | Merritt et al. | Jun 2012 | A1 |
| 20120209082 | Al-Ali | Aug 2012 | A1 |
| 20120209084 | Olsen et al. | Aug 2012 | A1 |
| 20120226117 | Lamego et al. | Sep 2012 | A1 |
| 20120283524 | Kiani et al. | Nov 2012 | A1 |
| 20130023775 | Lamego et al. | Jan 2013 | A1 |
| 20130033485 | Kollin | Feb 2013 | A1 |
| 20130041591 | Lamego | Feb 2013 | A1 |
| 20130046204 | Lamego et al. | Feb 2013 | A1 |
| 20130060147 | Welch et al. | Mar 2013 | A1 |
| 20130096405 | Garfio | Apr 2013 | A1 |
| 20130096819 | Tarnok | Apr 2013 | A1 |
| 20130096936 | Sampath et al. | Apr 2013 | A1 |
| 20130172759 | Melker et al. | Jul 2013 | A1 |
| 20130243021 | Siskavich | Sep 2013 | A1 |
| 20130296672 | O'Neil et al. | Nov 2013 | A1 |
| 20130324808 | Al-Ali et al. | Dec 2013 | A1 |
| 20130331660 | Al-Ali et al. | Dec 2013 | A1 |
| 20130345921 | Al-Ali et al. | Dec 2013 | A1 |
| 20140012100 | Al-Ali et al. | Jan 2014 | A1 |
| 20140051953 | Lamego et al. | Feb 2014 | A1 |
| 20140120564 | Workman et al. | May 2014 | A1 |
| 20140121482 | Merritt et al. | May 2014 | A1 |
| 20140127137 | Bellott et al. | May 2014 | A1 |
| 20140163344 | Al-Ali | Jun 2014 | A1 |
| 20140164022 | Reed et al. | Jun 2014 | A1 |
| 20140166076 | Kiani et al. | Jun 2014 | A1 |
| 20140171763 | Diab | Jun 2014 | A1 |
| 20140173674 | Wolman et al. | Jun 2014 | A1 |
| 20140180154 | Sierra et al. | Jun 2014 | A1 |
| 20140180160 | Brown et al. | Jun 2014 | A1 |
| 20140187973 | Brown et al. | Jul 2014 | A1 |
| 20140213864 | Abdul-Hafiz et al. | Jul 2014 | A1 |
| 20140228657 | Palley et al. | Aug 2014 | A1 |
| 20140257852 | Walker et al. | Sep 2014 | A1 |
| 20140275835 | Lamego et al. | Sep 2014 | A1 |
| 20140275871 | Lamego et al. | Sep 2014 | A1 |
| 20140275872 | Merritt et al. | Sep 2014 | A1 |
| 20140278536 | Zhang et al. | Sep 2014 | A1 |
| 20140288400 | Diab et al. | Sep 2014 | A1 |
| 20140316217 | Purdon et al. | Oct 2014 | A1 |
| 20140316218 | Purdon et al. | Oct 2014 | A1 |
| 20140316228 | Blank et al. | Oct 2014 | A1 |
| 20140323825 | Al-Ali et al. | Oct 2014 | A1 |
| 20140323897 | Brown et al. | Oct 2014 | A1 |
| 20140323898 | Purdon et al. | Oct 2014 | A1 |
| 20140330098 | Merritt et al. | Nov 2014 | A1 |
| 20140350966 | Khatana et al. | Nov 2014 | A1 |
| 20140357966 | Al-Ali et al. | Dec 2014 | A1 |
| 20140376789 | Xu et al. | Dec 2014 | A1 |
| 20150005600 | Blank et al. | Jan 2015 | A1 |
| 20150011907 | Purdon et al. | Jan 2015 | A1 |
| 20150032029 | Al-Ali et al. | Jan 2015 | A1 |
| 20150038859 | Dalvi et al. | Feb 2015 | A1 |
| 20150073241 | Lamego | Mar 2015 | A1 |
| 20150080754 | Purdon et al. | Mar 2015 | A1 |
| 20150087936 | Al-Ali et al. | Mar 2015 | A1 |
| 20150094546 | Al-Ali | Apr 2015 | A1 |
| 20150099950 | Al-Ali et al. | Apr 2015 | A1 |
| 20150101844 | Al-Ali et al. | Apr 2015 | A1 |
| 20150106121 | Muhsin et al. | Apr 2015 | A1 |
| 20150134107 | Hyde et al. | May 2015 | A1 |
| 20150134345 | Hyde | May 2015 | A1 |
| 20150141910 | Francis et al. | May 2015 | A1 |
| 20150173674 | Hayes et al. | Jun 2015 | A1 |
| 20150196249 | Brown et al. | Jul 2015 | A1 |
| 20150216459 | Al-Ali et al. | Aug 2015 | A1 |
| 20150238722 | Al-Ali | Aug 2015 | A1 |
| 20150257689 | Al-Ali et al. | Sep 2015 | A1 |
| 20150317891 | Day et al. | Nov 2015 | A1 |
| 20150351697 | Weber et al. | Dec 2015 | A1 |
| 20150366507 | Blank et al. | Dec 2015 | A1 |
| 20150367071 | Donnellan et al. | Dec 2015 | A1 |
| 20160019360 | Pahwa et al. | Jan 2016 | A1 |
| 20160029932 | Al-Ali | Feb 2016 | A1 |
| 20160058347 | Reichgott et al. | Mar 2016 | A1 |
| 20160066824 | Al-Ali et al. | Mar 2016 | A1 |
| 20160071392 | Hankey et al. | Mar 2016 | A1 |
| 20160081552 | Wojtczuk et al. | Mar 2016 | A1 |
| 20160095543 | Telfort et al. | Apr 2016 | A1 |
| 20160103598 | Al-Ali et al. | Apr 2016 | A1 |
| 20160129182 | Schuster | May 2016 | A1 |
| 20160166183 | Poeze et al. | Jun 2016 | A1 |
| 20160166766 | Schuster et al. | Jun 2016 | A1 |
| 20160189317 | Papandrea | Jun 2016 | A1 |
| 20160196388 | Lamego | Jul 2016 | A1 |
| 20160197436 | Barker et al. | Jul 2016 | A1 |
| 20160212404 | Maiello | Jul 2016 | A1 |
| 20160213281 | Eckerbom et al. | Jul 2016 | A1 |
| 20160228043 | O'Neil et al. | Aug 2016 | A1 |
| 20160263317 | Arefieg | Sep 2016 | A1 |
| 20160270735 | Diab et al. | Sep 2016 | A1 |
| 20160283665 | Sampath et al. | Sep 2016 | A1 |
| 20160287786 | Kiani | Oct 2016 | A1 |
| 20160314260 | Kiani | Oct 2016 | A1 |
| 20160324488 | Olsen | Nov 2016 | A1 |
| 20160327984 | Al-Ali et al. | Nov 2016 | A1 |
| 20160328993 | Brogioli | Nov 2016 | A1 |
| 20160367173 | Dalvi et al. | Dec 2016 | A1 |
| 20160371833 | Prasad et al. | Dec 2016 | A1 |
| 20170000394 | Al-Ali et al. | Jan 2017 | A1 |
| 20170007134 | Al-Ali et al. | Jan 2017 | A1 |
| 20170014083 | Diab et al. | Jan 2017 | A1 |
| 20170024748 | Haider | Jan 2017 | A1 |
| 20170042488 | Muhsin | Feb 2017 | A1 |
| 20170055882 | Al-Ali et al. | Mar 2017 | A1 |
| 20170055887 | Al-Ali | Mar 2017 | A1 |
| 20170055896 | Al-Ali | Mar 2017 | A1 |
| 20170079594 | Telfort et al. | Mar 2017 | A1 |
| 20170084133 | Cardinali et al. | Mar 2017 | A1 |
| 20170086723 | Al-Ali et al. | Mar 2017 | A1 |
| 20170094450 | Tu et al. | Mar 2017 | A1 |
| 20170143281 | Olsen | May 2017 | A1 |
| 20170147774 | Kiani | May 2017 | A1 |
| 20170156620 | Al-Ali et al. | Jun 2017 | A1 |
| 20170172522 | Insler | Jun 2017 | A1 |
| 20170173632 | Al-Ali | Jun 2017 | A1 |
| 20170188919 | Al-Ali et al. | Jul 2017 | A1 |
| 20170196464 | Jansen et al. | Jul 2017 | A1 |
| 20170196470 | Lamego et al. | Jul 2017 | A1 |
| 20170228516 | Sampath et al. | Aug 2017 | A1 |
| 20170245790 | Al-Ali et al. | Aug 2017 | A1 |
| 20170246390 | Tchao et al. | Aug 2017 | A1 |
| 20170251974 | Shreim et al. | Sep 2017 | A1 |
| 20170251975 | Shreim et al. | Sep 2017 | A1 |
| 20170262604 | Francois | Sep 2017 | A1 |
| 20170287316 | Wildman et al. | Oct 2017 | A1 |
| 20170293727 | Klaassen et al. | Oct 2017 | A1 |
| 20170311891 | Kiani et al. | Nov 2017 | A1 |
| 20170332952 | Desborough et al. | Nov 2017 | A1 |
| 20170332976 | Al-Ali | Nov 2017 | A1 |
| 20170340293 | Al-Ali et al. | Nov 2017 | A1 |
| 20170358242 | Thompson et al. | Dec 2017 | A1 |
| 20170360310 | Kiani | Dec 2017 | A1 |
| 20170366627 | Chan et al. | Dec 2017 | A1 |
| 20170372018 | Rosenblatt | Dec 2017 | A1 |
| 20180008146 | Al-Ali et al. | Jan 2018 | A1 |
| 20180013562 | Haider et al. | Jan 2018 | A1 |
| 20180014752 | Al-Ali et al. | Jan 2018 | A1 |
| 20180028124 | Al-Ali et al. | Feb 2018 | A1 |
| 20180035101 | Osterhout | Feb 2018 | A1 |
| 20180055390 | Kiani et al. | Mar 2018 | A1 |
| 20180055430 | Diab et al. | Mar 2018 | A1 |
| 20180064381 | Shakespeare et al. | Mar 2018 | A1 |
| 20180070867 | Smith et al. | Mar 2018 | A1 |
| 20180082767 | Al-Ali et al. | Mar 2018 | A1 |
| 20180085068 | Telfort | Mar 2018 | A1 |
| 20180087937 | Al-Ali et al. | Mar 2018 | A1 |
| 20180098698 | Marcus et al. | Apr 2018 | A1 |
| 20180103874 | Lee et al. | Apr 2018 | A1 |
| 20180103905 | Kiani | Apr 2018 | A1 |
| 20180110478 | Al-Ali | Apr 2018 | A1 |
| 20180110923 | Kaplan | Apr 2018 | A1 |
| 20180125368 | Lamego et al. | May 2018 | A1 |
| 20180125430 | Al-Ali et al. | May 2018 | A1 |
| 20180125445 | Telfort et al. | May 2018 | A1 |
| 20180130325 | Kiani et al. | May 2018 | A1 |
| 20180132769 | Weber et al. | May 2018 | A1 |
| 20180137932 | Fiedler et al. | May 2018 | A1 |
| 20180146901 | Al-Ali et al. | May 2018 | A1 |
| 20180146902 | Kiani et al. | May 2018 | A1 |
| 20180147343 | Tyson | May 2018 | A1 |
| 20180153442 | Eckerbom et al. | Jun 2018 | A1 |
| 20180153446 | Kiani | Jun 2018 | A1 |
| 20180153447 | Al-Ali et al. | Jun 2018 | A1 |
| 20180153448 | Weber et al. | Jun 2018 | A1 |
| 20180161499 | Al-Ali et al. | Jun 2018 | A1 |
| 20180168491 | Al-Ali et al. | Jun 2018 | A1 |
| 20180174261 | Brabazon | Jun 2018 | A1 |
| 20180174679 | Sampath et al. | Jun 2018 | A1 |
| 20180184917 | Kiani | Jul 2018 | A1 |
| 20180192924 | Al-Ali | Jul 2018 | A1 |
| 20180192953 | Shreim et al. | Jul 2018 | A1 |
| 20180192955 | Al-Ali et al. | Jul 2018 | A1 |
| 20180199871 | Pauley et al. | Jul 2018 | A1 |
| 20180200433 | Cirit | Jul 2018 | A1 |
| 20180206795 | Al-Ali | Jul 2018 | A1 |
| 20180206815 | Telfort | Jul 2018 | A1 |
| 20180213583 | Al-Ali | Jul 2018 | A1 |
| 20180214031 | Kiani et al. | Aug 2018 | A1 |
| 20180214090 | Al-Ali et al. | Aug 2018 | A1 |
| 20180218792 | Muhsin et al. | Aug 2018 | A1 |
| 20180225960 | Al-Ali et al. | Aug 2018 | A1 |
| 20180238718 | Dalvi | Aug 2018 | A1 |
| 20180242853 | Al-Ali | Aug 2018 | A1 |
| 20180242921 | Muhsin et al. | Aug 2018 | A1 |
| 20180242923 | Al-Ali et al. | Aug 2018 | A1 |
| 20180242924 | Barker et al. | Aug 2018 | A1 |
| 20180242926 | Muhsin et al. | Aug 2018 | A1 |
| 20180247353 | Al-Ali et al. | Aug 2018 | A1 |
| 20180247712 | Muhsin et al. | Aug 2018 | A1 |
| 20180253947 | Muhsin et al. | Sep 2018 | A1 |
| 20180256087 | Al-Ali et al. | Sep 2018 | A1 |
| 20180256113 | Weber et al. | Sep 2018 | A1 |
| 20180264242 | Hoffman et al. | Sep 2018 | A1 |
| 20180285094 | Housel et al. | Oct 2018 | A1 |
| 20180289325 | Poeze et al. | Oct 2018 | A1 |
| 20180289337 | Al-Ali et al. | Oct 2018 | A1 |
| 20180296161 | Shreim et al. | Oct 2018 | A1 |
| 20180300919 | Muhsin et al. | Oct 2018 | A1 |
| 20180310822 | Indorf et al. | Nov 2018 | A1 |
| 20180310823 | Al-Ali et al. | Nov 2018 | A1 |
| 20180317826 | Muhsin et al. | Nov 2018 | A1 |
| 20180317841 | Novak, Jr. | Nov 2018 | A1 |
| 20180333055 | Lamego et al. | Nov 2018 | A1 |
| 20180333087 | Al-Ali | Nov 2018 | A1 |
| 20190000317 | Muhsin et al. | Jan 2019 | A1 |
| 20190000362 | Kiani et al. | Jan 2019 | A1 |
| 20190015023 | Monfre | Jan 2019 | A1 |
| 20190021638 | Al-Ali et al. | Jan 2019 | A1 |
| 20190029574 | Schurman et al. | Jan 2019 | A1 |
| 20190029578 | Al-Ali et al. | Jan 2019 | A1 |
| 20190058280 | Al-Ali et al. | Feb 2019 | A1 |
| 20190058281 | Al-Ali et al. | Feb 2019 | A1 |
| 20190069813 | Al-Ali | Mar 2019 | A1 |
| 20190069814 | Al-Ali | Mar 2019 | A1 |
| 20190076028 | Al-Ali et al. | Mar 2019 | A1 |
| 20190082979 | Al-Ali et al. | Mar 2019 | A1 |
| 20190090748 | Al-Ali | Mar 2019 | A1 |
| 20190090760 | Kinast et al. | Mar 2019 | A1 |
| 20190090764 | Al-Ali | Mar 2019 | A1 |
| 20190117070 | Muhsin et al. | Apr 2019 | A1 |
| 20190117139 | Al-Ali et al. | Apr 2019 | A1 |
| 20190117140 | Al-Ali et al. | Apr 2019 | A1 |
| 20190117141 | Al-Ali | Apr 2019 | A1 |
| 20190117930 | Al-Ali | Apr 2019 | A1 |
| 20190122763 | Sampath et al. | Apr 2019 | A1 |
| 20190133525 | Al-Ali et al. | May 2019 | A1 |
| 20190142283 | Lamego et al. | May 2019 | A1 |
| 20190142344 | Telfort et al. | May 2019 | A1 |
| 20190150856 | Kiani et al. | May 2019 | A1 |
| 20190167161 | Al-Ali et al. | Jun 2019 | A1 |
| 20190175019 | Al-Ali et al. | Jun 2019 | A1 |
| 20190192076 | McHale et al. | Jun 2019 | A1 |
| 20190200941 | Chandran et al. | Jul 2019 | A1 |
| 20190201623 | Kiani | Jul 2019 | A1 |
| 20190209025 | Al-Ali | Jul 2019 | A1 |
| 20190209084 | Bryant et al. | Jul 2019 | A1 |
| 20190214778 | Scruggs et al. | Jul 2019 | A1 |
| 20190216317 | Grande | Jul 2019 | A1 |
| 20190216319 | Poeze et al. | Jul 2019 | A1 |
| 20190216321 | Grande | Jul 2019 | A1 |
| 20190216379 | Al-Ali et al. | Jul 2019 | A1 |
| 20190221320 | Amini et al. | Jul 2019 | A1 |
| 20190221966 | Kiani et al. | Jul 2019 | A1 |
| 20190223804 | Blank et al. | Jul 2019 | A1 |
| 20190231199 | Al-Ali et al. | Aug 2019 | A1 |
| 20190231241 | Al-Ali et al. | Aug 2019 | A1 |
| 20190231270 | Abdul-Hafiz et al. | Aug 2019 | A1 |
| 20190239787 | Pauley et al. | Aug 2019 | A1 |
| 20190239824 | Muhsin et al. | Aug 2019 | A1 |
| 20190254578 | Lamego | Aug 2019 | A1 |
| 20190261857 | Al-Ali | Aug 2019 | A1 |
| 20190269370 | Al-Ali et al. | Sep 2019 | A1 |
| 20190274606 | Kiani et al. | Sep 2019 | A1 |
| 20190274627 | Al-Ali et al. | Sep 2019 | A1 |
| 20190274635 | Al-Ali et al. | Sep 2019 | A1 |
| 20190290136 | Dalvi et al. | Sep 2019 | A1 |
| 20190298270 | Al-Ali et al. | Oct 2019 | A1 |
| 20190304601 | Sampath et al. | Oct 2019 | A1 |
| 20190304605 | Al-Ali | Oct 2019 | A1 |
| 20190307377 | Perea et al. | Oct 2019 | A1 |
| 20190320906 | Olsen | Oct 2019 | A1 |
| 20190320959 | Al-Ali | Oct 2019 | A1 |
| 20190320988 | Ahmed et al. | Oct 2019 | A1 |
| 20190325722 | Kiani et al. | Oct 2019 | A1 |
| 20190336085 | Kayser | Nov 2019 | A1 |
| 20190374139 | Kiani et al. | Dec 2019 | A1 |
| 20190374173 | Kiani et al. | Dec 2019 | A1 |
| 20190374713 | Kiani et al. | Dec 2019 | A1 |
| 20200021930 | Iswanto et al. | Jan 2020 | A1 |
| 20200054250 | Joseph et al. | Feb 2020 | A1 |
| 20200054278 | Joseph | Feb 2020 | A1 |
| 20200060869 | Telfort et al. | Feb 2020 | A1 |
| 20200066415 | Hettig | Feb 2020 | A1 |
| 20200101166 | Jenkins | Apr 2020 | A1 |
| 20200111552 | Ahmed | Apr 2020 | A1 |
| 20200113435 | Muhsin | Apr 2020 | A1 |
| 20200113488 | Al-Ali et al. | Apr 2020 | A1 |
| 20200113496 | Scruggs et al. | Apr 2020 | A1 |
| 20200113497 | Triman et al. | Apr 2020 | A1 |
| 20200113520 | Abdul-Hafiz et al. | Apr 2020 | A1 |
| 20200129117 | Henderson | Apr 2020 | A1 |
| 20200138288 | Al-Ali et al. | May 2020 | A1 |
| 20200138368 | Kiani et al. | May 2020 | A1 |
| 20200163597 | Dalvi et al. | May 2020 | A1 |
| 20200196877 | Vo et al. | Jun 2020 | A1 |
| 20200253474 | Muhsin et al. | Aug 2020 | A1 |
| 20200253544 | Belur Nagaraj et al. | Aug 2020 | A1 |
| 20200262864 | Barbut | Aug 2020 | A1 |
| 20200275841 | Telfort et al. | Sep 2020 | A1 |
| 20200288983 | Telfort et al. | Sep 2020 | A1 |
| 20200321793 | Al-Ali et al. | Oct 2020 | A1 |
| 20200329983 | Al-Ali et al. | Oct 2020 | A1 |
| 20200329984 | Al-Ali et al. | Oct 2020 | A1 |
| 20200329993 | Al-Ali et al. | Oct 2020 | A1 |
| 20200330037 | Al-Ali et al. | Oct 2020 | A1 |
| 20200405226 | Kiani et al. | Dec 2020 | A1 |
| 20210022628 | Telfort et al. | Jan 2021 | A1 |
| 20210074142 | Payment | Mar 2021 | A1 |
| 20210104173 | Pauley et al. | Apr 2021 | A1 |
| 20210113121 | Diab et al. | Apr 2021 | A1 |
| 20210117525 | Kiani et al. | Apr 2021 | A1 |
| 20210118581 | Kiani et al. | Apr 2021 | A1 |
| 20210121582 | Krishnamani et al. | Apr 2021 | A1 |
| 20210161465 | Barker et al. | Jun 2021 | A1 |
| 20210236729 | Kiani et al. | Aug 2021 | A1 |
| 20210256267 | Ranasinghe et al. | Aug 2021 | A1 |
| 20210256835 | Ranasinghe et al. | Aug 2021 | A1 |
| 20210275101 | Vo et al. | Sep 2021 | A1 |
| 20210290060 | Ahmed | Sep 2021 | A1 |
| 20210290072 | Forrest | Sep 2021 | A1 |
| 20210290080 | Ahmed | Sep 2021 | A1 |
| 20210290120 | Al-Ali | Sep 2021 | A1 |
| 20210290177 | Novak, Jr. | Sep 2021 | A1 |
| 20210290184 | Ahmed | Sep 2021 | A1 |
| 20210296008 | Novak, Jr. | Sep 2021 | A1 |
| 20210330228 | Olsen et al. | Oct 2021 | A1 |
| 20210386382 | Olsen et al. | Dec 2021 | A1 |
| 20210402110 | Pauley et al. | Dec 2021 | A1 |
| 20220026355 | Normand et al. | Jan 2022 | A1 |
| 20220039707 | Sharma et al. | Feb 2022 | A1 |
| 20220053892 | Al-Ali et al. | Feb 2022 | A1 |
| 20220071562 | Kiani | Mar 2022 | A1 |
| 20220096603 | Kiani et al. | Mar 2022 | A1 |
| 20220151521 | Krishnamani et al. | May 2022 | A1 |
| 20220218244 | Kiani et al. | Jul 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 2017-518834 | Jul 2017 | JP |
| WO-2017139761 | Aug 2017 | WO |
| WO 2018065284 | Apr 2018 | WO |
| WO 2018094520 | May 2018 | WO |
| WO 2018110510 | Jun 2018 | WO |
| WO 2018020911 | Jul 2018 | WO |
| WO 2019236759 | Dec 2019 | WO |
| WO 2021189007 | Sep 2021 | WO |
| Entry |
|---|
| US 2022/0192529 A1, 06/2022, Al-Ali et al. (withdrawn) |
| A “Second Chance” to Prevent Opioid Deaths, Technology Networks, Informatics News, This App Uses Sonar to Detect Opioid Overdoses, University of Washington, Jan. 10, 2019, in 3 pages, https://www.technologynetworks.com/informatics/news/a-second-chance-to-prevent-opioid-deaths-313744. |
| Announcing the Winner of the 2016 FDA Naloxone APP Competition, U.S. Food & Drug Administration, dated 2016, in 2 pages. https://www.fda.gov/news-events/public-health-focus/announcing-winner-2016-fda-naloxone-app-competition. |
| Blair, Andre, Monitoring For Opioid Overdoses: HopeBand Can Save People's Life, Advocator, dated Dec. 28, 2018 in 2 pages, https://advocator.ca/news/monitoring-for-opioid-overdoses-hopeband-can-save-peoples-life. |
| England, Rachel, “Wearable Sensor Can Detect Imminent Opioid Overdose, The low-cost device gives wearers the opportunity to administer life-saving drugs”, Engadget, https//www.engadget.com/2018/12/28/wearable-sensor-opioid-overdose/?guccounter=1. Dec. 28, 2018, in 3 pages. |
| Hsu, Jeremy, Wristband That Detects Opioid Overdose Joins U.S. Race for Tech Solutions, IEEE Spectrum's Biomedical Engineering Blog, dated Dec. 26, 2018, in 2 pages. |
| International Search Report and Written Opinion received in PCT Application No. PCT/US2019/035664, dated Nov. 6, 2019 in 17 pages. |
| McKibben, Justin, OD Help App Could Make Getting Naloxone Like Getting an Uber, Palm Partners Drug Rehab Center, 2018, in 7 pages. https://www.palmpartners.com/od-help-app-naloxone-uber/. |
| Muoio, Dave, “Robert Wood Johnson Foundation Names Winners of $50,000 AI, Opioid Challenges”, Mobihealthnews, dated Sep. 19, 2018, in 13 pages, https://www.mobihealthnews.com/content/robert-wood-johnson-foundation-names-winners-50000-ai-opioid-challenges. |
| Middlebrook, Hailey, OD Help app wins FDA's competition to help fight heroin overdose, CNN, dated Dec. 19, 2016, in 4 pages, https://www.cnn.com/2016/09/22/health/fda-heroin-app-competition/index.html. |
| “OD Help”, PwrdBy, published Nov. 7, 2016, https://www.youtube.com/watch?v=wiiNvSLbUgo in 1 page. |
| Opioid Overdose, SAMHSA—Substance Abuse and Mental Health Services Administration, retrieved Jul. 2, 2019, in 2 pages. http://www.samhsa.gov/medication-assisted-treatment/treatment/opioid-overdose. |
| Singer, “Pill dispenser that's set by timer may stop opioid addiction before it starts” https://www.democratandchronicle.com , May 8, 2018, in 6 pages. |
| Young, Grace, “NALNOW—2016 FDA Naloxone App Competition”, Nov. 7, 2016, retrieved from https://www.youtube.com/watch?v=DKsHBJm9uNc&feature=youtu.be. |
| International Search Report and Written Opinion received in PCT Application No. PCT/US2021/023336, dated Jun. 25, 2021 in 12 pages. |
| Nandakumar et al., “Opioid Overdose Detection Using Smartphones”, Science Translational Medicine, vol. 11, No. 474, Research Article, Jan. 9, 2019, pp. 10. |
| Number | Date | Country | |
|---|---|---|---|
| 20210128078 A1 | May 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62681309 | Jun 2018 | US | |
| 62716469 | Aug 2018 | US | |
| 62733314 | Sep 2018 | US | |
| 62745031 | Oct 2018 | US | |
| 62792998 | Jan 2019 | US | |
| 62810156 | Feb 2019 | US | |
| 62836855 | Apr 2019 | US | |
| 62745243 | Oct 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16432739 | Jun 2019 | US |
| Child | 17145663 | US |
